Key Benefits:
ACT
of 29 July 2005
anti-drug addiction
Chapter 1
General provisions
Article 1. [ Regulatory scope] The Act shall specify:
1) the rules and the procedure for dealing with drug addiction;
2) the tasks and powers of the authorities of government administration and local government units and other entities to counteract violations of the law on the marketing, manufacture, processing, processing and possession of substances, which the use may lead to drug addiction;
(3) the competent authorities to implement:
(a) Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004. on drug precursors (Dz. Urz. EC L 047 of 18.02.2004), hereinafter referred to as 'Regulation 273/2004',
(b) of Council Regulation (EC) No 111/2005 of 22 December 2004. laying down rules for the supervision of trade in drug precursors between the Community and third countries (Dz. Urz. EC L 22 of 26.01.2005, p. 1; Dz. Urz. EC Polish special edition 2005, t. 48, str. 1), hereinafter referred to as "Regulation 111/2005";
4) penalties for failure to comply with the provisions of the Act and Regulations mentioned in point 3.
Article 2. [ Anti-drug addiction tasks] 1. The addiction of drug addiction is carried out by the appropriate shaping of social, economic, educational and educational policies, and in particular:
1) educational, educational, information and prophylactic activities;
2) treatment, rehabilitation and reintegration of addicts;
3) reducing health and social damage;
4. the supervision of substances which may lead to drug addiction;
5. combating the unauthorised circulation, manufacture, processing, processing and possession of substances the use of which is likely to lead to drug addiction;
6) supervision of plant crops containing substances whose use may lead to drug addiction.
2. [ 1] The tasks referred to in paragraph 1. Article 1 (1) (1) (1), (1) (1), (1) (1), (1) (a), (1) (1), (3) and (3), 48 (1) 1 of the Act of 27 August 2004. on health care services financed from public funds (Dz. U. of 2015 items 581, as late. zm.), and National Health Fund resources other than those intended for the implementation of health programmes.
3. The tasks referred to in paragraph. Article 1 (1) (a) of the European Parliament and of the Council of the European Parliament and of the Council of Ministers of the European Union
Article 3. [ Application of provisions of the Act] The provisions of the Act shall apply to:
1) medicinal products which are narcotic drugs, psychotropic substances or precursors, in the unregulated range in the Act of 6 September 2001. -Pharmaceutical law (Dz. U. of 2008 Nr 45, poz. 271, with late. zm.);
2) chemical substances and their mixtures, which are precursors, to the extent unregulated by the regulations on chemical substances and their mixtures.
Article 4. [ Definitions] The terms used in the Act shall mean:
1) hallucinogenic mushrooms-fungi containing psychotropic substances;
2. the importer-a natural person, a legal person or an entity which does not have legal personality, which imports and submits a customs declaration or on whose behalf the customs declaration is lodged;
3) scientific units-scientific units within the meaning of art. 2 point 9 of the Act of 30 April 2010. on the principles of financing science (Dz. U. Nr 96, pos. 615 and 2011 Nr 84, pos. 455 and No. 185, pos. 1092);
4. hemp-hemp plants (Cannabis L.);
5. hemp hemp (Cannabis sativa L.), where the sum of the delta-9-tetra-hydrocannabinol content and tetrahydrocannabinol acid (delta-9-THC-2-carboxylic acid) in floral or fruiting vertices the plants from which the resin has not been removed shall not exceed 0,20% on the dry weight basis;
6) treatment-treatment of psychiatric disorders and behaviour disorders caused by the use of narcotic drugs or psychotropic substances;
7) substitution therapy-the use of medicinal products or drugs of agonistic action on the opioid receptor as part of a treatment programme for addiction;
8) poppy-a plant of the species poppy (Papaver somniferum L.), also known as garden poppy or cultivated poppy seed;
9. Nicodorine poppy seed-a plant of the species of poppy-flavour belonging to a variety in which the content of morphine in the bag (makówka) without seeds, together with the adjoining stem of up to 7 cm, is less than 0,06% calculated on the morphine and dry basis the weight of the said parts of
10) poppy milk-juice milk purse (makings) of poppy;
11. exposure-permanent or periodic use for purposes other than medical intoxicants, psychotropic substances, surrogate agents or new psychoactive substances, as a result of which may arise or become an addiction to them;
11a) a new psychoactive substance-a substance of natural or synthetic origin in any physical state, having an action on the central nervous system, as defined by the provisions adopted on the basis of art. 44b (b) 2;
12) a reduction in health and social damage-actions aimed at reducing health and social problems arising from use for purposes other than medical intoxicants, psychotropic substances, surrogate measures or new psychoactive substances;
13) opium-concentrated milk juice (macabas) of poppy;
14) a person at risk of addiction-a person whose team of mental phenomena and environmental interactions creates a high probability of being dependent on narcotic drugs or psychotropic substances, or a person who is intermittently using narcotic drugs, psychotropic substances, surrogate agents or new psychoactive substances;
15. an addict-person who, as a result of the use of narcotic drugs, psychotropic substances, surrogate agents or new psychoactive substances, or uses them for medical purposes is in a state of addiction to these measures or substances;
16) precursor-a drug precursor which is a classified substance referred to in art. 2 point a of Regulation (EC) No 273/2004, the category of which is set out in Annex 1 to that Regulation;
17. preparation-a medicinal product containing one or more narcotic drugs or psychotropic substances or their precursors;
18) producer-entrepreneur producing, transforming or processing narcotic drugs, psychotropic substances or precursors;
19) processing-operations leading to the transformation of narcotic drugs, psychotropic substances or precursors to other narcotic drugs, psychotropic substances or precursors or to substances other than narcotic drugs, substances psychotropic or precursors;
20) reprocessing-receiving mixtures of narcotic drugs, psychotropic substances or precursors, and giving these measures or substances of the form used in the treatment of the medicinal product;
20a) carriage-any transfer of narcotic drugs, psychotropic substances or manic straw between two states through the territory of the Republic of Poland, which starts and ends outside of that territory;
21. imports-any introduction into the customs territory of the European Union of narcotic drugs, psychotropic substances, surrogate agents or new psychoactive substances;
22) rehabilitation-a process in which a person with psychiatric disorders caused by the intake of narcotic drugs or psychotropic substances achieves optimal health, mental and social functioning;
23) reintegration-the effect of the actions set out in art. 14-16 and art. 18 of the Act of 13 June 2003. with social employment (Dz. U. of 2011 r. Nr 43, pos. 225 and No. 205, pos. 1211);
24) poppy straw-a purse (makebook) without seed, including the stem, or the individual parts of them;
25) a psychotropic substance-any substance of natural or synthetic origin, acting on the central nervous system, as defined in the list of psychotropic substances constituting Annex No. 2 to the Act;
26. intoxicating agent-any substance of natural or synthetic origin acting on the central nervous system, as defined in the list of intoxicants of Annex No 1 to the Act;
27) replacement measure-a product containing at least one new psychoactive substance or other substance with a similar effect on the central nervous system, which may be used in place of a narcotic or psychotropic substance or in such a way the purposes themselves, such as a narcotic or psychotropic substance, the manufacture and placing on the market of which is not regulated by separate provisions; whereas the provisions on general safety of products shall not apply to substitution measures;
28. the cultivation of poppy or hemp-any crop of poppy or hemp regardless of the surface;
29) dependence on narcotic drugs or psychotropic substances-a team of psychiatric or somatic phenomena resulting from the effects of narcotic drugs or psychotropic substances on the human body, characterized by change of behaviour or other psychophysical reactions and the need to use continuously or periodically these means or substances in order to have their influence on the psyche or to avoid consequences caused by the absence thereof;
30) using harmful substances-using a psychoactive substance causing somatic or mental damage, including a disability of judging or dysfunctional behaviour which can lead to disability or have undesirable consequences for relationships with other people;
(31) use of a narcotic, psychotropic substance, a replacement or a new psychoactive substance-the introduction into the human organism of a narcotic, psychotropic substance, a replacement or a new substance psychoactive, regardless of route of administration;
32) intra-Community supply-the movement of narcotic drugs or psychotropic substances from the territory of the Republic of Poland within the territory of a Member State of the European Union;
33) intra-Community acquisitions-the movement of narcotic drugs or psychotropic substances from the territory of a Member State of the European Union within the territory of the Republic of Poland;
34. placing on the market-making available to third parties, whether in return for payment or free of charge, of narcotic drugs, psychotropic substances, precursors, surrogate agents or new psychoactive substances;
35) manufacture-operations by which narcotic drugs, psychotropic substances, precursors, replacement agents or new psychoactive substances may be obtained, their purification, extraction of raw materials and intermediate products and the receipt of salts those measures or substances;
36) export-any exit from the customs territory of the European Community of narcotic drugs or psychotropic substances;
37) hemp of hemp other than non-wovens-each terrestrial part of a hemp plant (single or in a mixture), excluding seeds, containing more than 0,20% of the sum of delta-9-tetrahydrocannabinol and tetrahydrocannabinol acid (acid) delta-9-THC-2-carboxylic);
38) hemp resin-resin and other cannabis products containing delta-9-tetrahydrocannabinol or other biologically active cannabinols.
Chapter 2
Entities performing tasks in the field of drug addiction
Article 5. [ The bodies carrying out the tasks of counteracting drug addiction] 1. Drug prevention tasks shall be carried out by the authorities of governmental administration and local government units within the scope set out in the Act.
2. The tasks of counteracting drug addiction shall be carried out, to the extent specified by the law, also by:
1) kindergartens, schools and other organizational units mentioned in art. 2 points 3-5 and 7-9 of the Act of 7 September 1991. o system of education (Dz. U. of 2004 Nr 256, pos. 2572, as of late. zm.);
2) higher education;
3) medical agents and other health care providers;
4) units of the Polish Army, Police and Border Guards;
5. customs bodies;
6. Organizational units of the Prison Service and correcting facilities and shelters for minors;
7) social assistance centres, county aid centres and regional social policy centres;
7a) the organisational units of family support and replacement roast system referred to in art. 2. 3 of the Act of 9 June 2011. to support family and foster care system (Dz. U. of 2015 items 332), and family assistants, foster families and family members of the child's homes;
8. mass media.
3. In the performance of the tasks referred to in art. 2. 1, may non-governmental organizations and other entities whose statutory activities include tasks belonging to the sphere of public tasks in the scope of protection and promotion of health, social assistance, charity, science, education, education and education, physical culture, order and public security or countering social pathologies, promotion and voluntary organisation, following the competition referred to in art. 11 (1) 2 of the Act of 24 April 2003. about the activity of the public benefit and about the volunteer (Dz. U. of 2010 No 234, pos. 1536, as of late. zm.), as well as the self-government of the medical professions, the families of addicts, and the self-help groups of addicts and their families.
Article 6. [ National Bureau of Action Against Drug Addiction] 1. Drug prevention activities shall be conducted by the National Action Office of Drug Addiction, hereinafter referred to as the 'Office'.
2. The Office shall be the budgetary unit subordinate to the Minister responsible for health.
3. The tasks of the Office shall be:
1) [ 2] (repealed);
2) [ 3] (repealed);
3) the execution of drug prevention tasks, consisting in the entrustment and support of the execution of public tasks, together with the grant of grants to finance their implementation on the basis of the power of attorney of the minister competent for health matters;
4) initiating actions aimed at limiting the use of narcotic drugs, psychotropic substances, surrogate agents or new psychoactive substances;
5. initiating, supporting and conducting analyses and research into drug addiction, including the drawing up of an epidemiological evaluation of the risks of drug addiction;
6) initiate work on new legislative solutions to counteract drug addiction;
7) making periodic evaluations of prophylactic, therapeutic, rehabilitation and readaptive programs in terms of their effectiveness in limiting the use of narcotic drugs, psychotropic substances, surrogate agents or new psychoactive substances;
8) developing standards for the prevention of addiction and the treatment and rehabilitation of addicts;
9) initiate, organize and conduct trainings for persons performing tasks in the field of counteracting drug addiction;
10) providing assistance to professionals carrying out drug prevention tasks, including local government units, as well as educational, research, prophylactic, medical, educational, educational, educational, educational, and educational activities. rehabilitative and reintegration;
11. cooperation with international organisations operating in the field of counteracting drug addiction and winding up of damage caused by it;
(12) the operation of a national drug information system and the monitoring of drug prevention activities at national and international level, including:
(a) the collection, collection, exchange of information and documentation for the prevention of drug addiction, covered by statistical surveys of the public statistics, and the development and processing of data collected,
(b) the conduct and initiation of studies on drug and drug addiction problems and the development and making available of results,
(c) the collection, storage and making available of databases on drugs and drug addiction;
(d) the formulation of proposals favouring the development of an appropriate response strategy to the problem of drug addiction,
(e) coordinating the activities of the voivodship experts referred to in art. 9 ust. 6,
(f) the collection and making available of publications on drugs and drug addiction;
(g) the role of focal point of the European Monitoring Centre for Drugs and Drug Addiction;
(h) participation in the work of reporting to international organisations;
(i) cooperation with the European Monitoring Centre for Drugs and Drug Addiction and the European Network of Information on Drugs and Drug Addiction (Reitox),
(j) developing and publishing an annual report on the state of drug addiction in Poland,
k) [ 4] (repealed);
13. undertaking intervention measures in the cases of complaints and applications concerning the problem of drug addiction, addressed to the Office or to the Minister responsible for health matters;
14) the performance of other counteracting tasks, commissioned by the Minister responsible for health;
14a) subsidising the costs of training in the field of addiction;
15) technical-organizational support of the Council for the counteraction of Narkomania.
4. The Office, in carrying out the tasks referred to in the paragraph. 3, shall cooperate with the public administration bodies performing the tasks referred to in art. 2, and may create working teams.
5. The tasks referred to in paragraph. The Centre for Drugs and Drug Addiction, which is an organisational cell of the Bureau, is implementing the Information Centre on Drugs and Drug Addiction 3,
Article 7. [ National Health Programme] [ 5] The National Health Programme referred to in art is the basis for action on drug addiction. 9 ust. 1 of the Act of 11 September 2015. with public health (Dz. U. Entry 1916), hereinafter referred to as the "National Health Programme".
Article 8. [ 6] (repealed).
Article 9. [ Provincial Drug Addiction Program] 1. [ 7] The executive body of the provincial government is developing the project of the Voivodship Programme Against Drug Addiction, hereinafter referred to as the "Voivodship Programme", taking into account the operational objectives of counteracting drug addiction, as defined in the National Programme Health. The Voivodship Program forms part of the voivodship strategy on social policy.
2. Voivodship Program is enacted by the state's purse seismik.
3. The executive body of the provincial government:
1) responsible for the preparation of the project of the Voivodship Programme and its implementation and coordination;
2) provide factual assistance to entities carrying out tasks covered by the Provincial Programme;
3) co-operates with other public administration bodies in the field of counteracting drug addiction.
4. The Provincial Program shall be implemented by the entity indicated in this programme.
5. In order to carry out the tasks referred to in paragraph. 3 point 1, the executive body of the self-government of the voivodship may appoint a proxy.
6. The executive body of the self-government of the voivodship appoints and refers to the provincial expert for information on drugs and drug addiction.
7. The tasks of the voivodship expert for information on drugs and drug addiction, carried out in the voivodship from the measures specified in the budget of the provincial government, shall be:
1) the collection, collection, exchange of information and documentation in the field of drug prevention, covered by statistical surveys of public statistics, and the development and processing of collected data;
2) conducting and initiating research on the problems of drugs and drug addiction and the development and making available of their results;
3) the collection, storage and making available of databases on drugs and drug addiction;
4. formulating proposals to promote an adequate response to the situation of drug addiction strategies;
5) collection and sharing of publications on drugs and drug addiction;
6) collection and analysis of information on emerging trends in the use of narcotic drugs, psychotropic substances, surrogate agents or new psychoactive substances.
Article 10. [ Municipal Drug Addiction Programme] 1. The addiction of drug addiction is one of the communes ' own tasks, covering:
1. increasing the availability of therapeutic and rehabilitation aid to addicts and persons at risk of addiction;
2) giving families in which there are problems of drug addiction, psychosocial and legal assistance;
3) carrying out preventive information, educational and training activities in the field of problem solving of drug addiction, in particular for children and young people, including the conduct of sports and recreational activities for students, as well as activities on the benefit of the children participating in the extra-curricular care and socio-therapeutic programmes;
4) assisting the activities of institutions, non-governmental organisations and individuals to address the problems of drug addiction;
5) social assistance to addicts and families of addicts affected by poverty and social exclusion and integrating them into the local environment through social work and a social contract.
2. [ 8] Wójt (Mayor, Mayor of the City) in order to carry out the tasks referred to in paragraph. 1, develops the project of the Municipal Drug Addiction Programme, hereinafter referred to as the "Municipal Programme", taking into account the operational objectives of drug addiction, as set out in the National Health Programme. The Municipal Programme is a part of the municipal strategy for solving social problems.
3. The Gminny Program is enacted by the municipal council.
4. The Gminny Program is carried out by the entity indicated in this program.
5. In order to carry out the tasks referred to in paragraph. 1, Yvt (Mayor, Mayor of the City) can appoint a proxy.
Article 11. [ Information on the implementation of the Voivodship Programme and the Gminny Program] 1. The executive body of the self-government of the voivodship and the municipality shall draw up a report on the implementation in the given year of the Voivodship Programme and the Gminny Programme and the effects of their implementation, which shall submit accordingly to the Sejmik of the voivodship or council of the municipality, by the March of the year following the year to which the report relates.
2. The executive body of the self-government of the voivodship and the municipality shall draw up, on the basis of the survey conducted by the Bureau, information on the implementation of the activities undertaken in the given year, resulting from the Voivodship and the Gminny Programme, and send it to the Office, within a period of time on 15 April of the year following the year to which the information relates.
Article 12. [ Narkomania's Action Council] 1. A Council for the Oppression of Drug Addiction, hereinafter referred to as 'the Council', shall be established.
2. The Council acts by the President of the Council of Ministers.
3. The Council shall be the coordination and advisory body in the field of drug addiction.
4. The President of the Council of Ministers shall determine, by way of ordinance, the statutes of the Council, taking into account the detailed conditions and mode of its operation, including the manner of working of the working teams referred to in art. 17.
Article 13. [ Composition of the Council] 1. The members of the Council shall appoint and dismiss the President of the Council of Ministers.
2. The Council shall consist of:
1. Chairman-Secretary or Undersecretary of State in the office serving the Minister responsible for health matters;
2. Deputy Chairman-Secretary or Under-Secretary of State in the office serving the Minister responsible for internal affairs;
3. Secretary-Director of the Office;
4. the members, secretaries or subsecretaries of the State, in the offices serving the ministers:
(a) Justice,
(b) appropriate for education and education,
(c) National Defence,
(d) appropriate for agricultural matters,
(e) the competent social security case,
(f) competent for public finances, Head of the Customs Service,
(g) competent for foreign affairs,
(h) competent for scientific matters,
(i) the relevant economic affairs;
5) a member-a representative of the local government in the Commission of the Joint Government and the Local Government, by which it is indicated.
3. Meetings of the Council shall be convened at least 2 times a year.
Article 14. [ Council reference] 1. The President of the Council of Ministers shall cancel the member of the Council due
1) to resign;
2. not participating in the work of the Council;
3) the submission of an application for its appeal by the entity of which the person is representative;
4) sentencing a final sentence for a deliberate offence or a deliberate tax offence.
2. In the event of a cancellation or death of a member of the Council, the competent body shall submit an application for appointment of another representative to the member
Article 15. [ Council tasks] The tasks of the Council shall be in particular:
1) to monitor and coordinate the implementation of the state policy in the area of narcotic drugs, psychotropic substances, precursors, surrogate agents or new psychoactive substances;
2) presence to the Minister of the competent for health matters in matters concerning the creation, changes and additions to national strategies and plans to counteract problems caused by the marketing and use of narcotic drugs, psychotropic substances and precursors;
3) monitoring information on the implementation of national strategies and action plans;
4) [ 9] monitoring the implementation of the National Health Programme in the field of drug prevention activities;
5) recommending organizational solutions in the scope of counteracting drug addiction;
6) co-operate with the entities referred to in art. 5, in the field of problems concerning the activities of the Council.
Article 16. [ Participation of experts in Council meetings] The President of the Council may invite experts dealing with the prevention of drug addiction to participate in the meetings of the Council.
2. The Council shall deliver opinions and submit proposals in the form of resolutions by a majority of votes.
Article 17. [ Work Team] In order to carry out the tasks of the Council, the President of the Council may set up working teams, composed of members of the Council or other persons, in particular specialists dealing with the prevention of drug addiction.
Article 18. [ Reimbursement of travel expenses for members of the Council 1. No remuneration shall be paid for participation in the work of the Council.
2. Members of the Council shall be entitled to reimbursement of travel expenses on the basis of the rules laid down in the provisions adopted pursuant to Article 77 5 § 2 of the Labour Code.
Art. 18a. [ The risk assessment team for the health or life of humans associated with the use of new psychoactive substances] 1. The Minister of Health shall set up a team to assess the risks to health or life of people associated with the use of new psychoactive substances, hereinafter referred to as the "Team".
2. The team is an advisory and advisory body of the minister competent for health issues on the assessment of potential risks to the health or life of humans or the possibility of causing social damage, arising from the use of substances in which it exists the suspicion that they are acting on the central nervous system.
3. The members of the team shall be specialists in the matters referred to in the paragraph. 2, having knowledge of at least the scope of chemical sciences, pharmacology, toxicology, psychiatry, social sciences or legal sciences.
4. The composition of the Team includes:
1) the members appointed by the minister competent for health matters, including the President and the Deputy Chairman;
2. members appointed by the Minister responsible for health at the request:
(a) the Minister of Justice,
(b) Minister of National Defence,
(c) the Minister responsible for internal affairs,
(d) the minister responsible for economic affairs,
(e) the minister responsible for transport.
5. The Minister of Health Affairs refers to a member of the Team:
1) on its own initiative, after consulting the authority which requested the appointment of a member of the Team, or
2) at the request of the body which requested the appointment of a member of the Team, or
3) at its own request of a member of the Team.
6. The team's administrative support shall be provided by the Chief Sanitary Inspectorate.
7. The Minister of Health shall determine, by means of ordinance, the organisational regulations of the Team, taking into account its tasks and the composition of the staff.
Art. 18b. [ Team Tasks] 1. The tasks of the Team shall be:
1) an assessment of the potential risks to the health or life of humans or the possibility of causing social damage, arising from the use of substances suspected to be acting on the central nervous system;
2. evaluation of a non-new psychoactive substance, but showing an action on the central nervous system, which poses a direct risk to the health or life of humans or causing social harm, justifying its inclusion in the list new psychoactive substances or in the list of narcotic drugs or psychotropic substances;
3) recommendation of the Minister competent for the health of changes in the annexes to the Act and regulations issued on the basis of art. 44b (b) 2.
2. The Minister of Health shall make public, through its website, the Public Information Bulletin, the evaluation and recommendations of the Team referred to in paragraph 1. 1 points 2 and 3.
Art. 18c. [ Remuneration for participation in the work of the Team] 1. The participation in the work of the Team shall not be entitled to remuneration.
2. The members of the team shall be entitled to reimbursement of travel expenses on the basis specified in the provisions issued on the basis of art. 77 5 § 2 of the Labour Code.
Art. 18d. [ Appointment of experts] The Chairperson of the Team shall, on his own initiative or at the request of a Member of the Team, may appoint experts to present opinions or to participate in the work of the Team.
Chapter 3
Educational, educational, information and prophylactic activities
Article 19. [ Scope of educational, educational, information and prophylactic activities] 1. Educational, educational, information and prophylactic activities include:
1) the promotion of mental health;
2) the promotion of a healthy lifestyle;
3. to inform about the harmfulness of the means and substances the use of which may lead to drug addiction, and of the drug addiction and its effects;
4) psychology and social education;
5) legal education;
6. intervention measures.
2. The activities referred to in paragraph 2. 1, includes in particular:
1) introducing the problem of drug prevention to the educational programs of the educational system units of the education system;
2. introducing the prevention of drug addiction to vocational training programmes for those involved in the education and prevention of education in schools and other educational establishments, and in higher education institutions;
3) introduction of the problem of preventing drug addiction to the training programmes of soldiers in active military service;
4) conducting prevention activities, in particular in environments at risk of addiction;
5) support the activities of the nationwide and local organisations referred to in art. 5 par. 3, as well as other social initiatives;
6. taking into account the problem of the prevention of drug addiction in the activities of public broadcasting and other media;
7) conducting scientific research on drug addiction.
3. [ 10] Detailed tasks in the field of educational, educational, information and prophylactic activities are defined by the National Health Programme.
Article 20. [ Advertisement] 1. The advertising and promotion of psychotropic substances or narcotic drugs is prohibited.
2. Medicinal products containing psychotropic substances or narcotic drugs may be advertised in accordance with the rules laid down in the Act of 6 September 2001. -Pharmaceutical law.
3. The advertising and promotion of foodstuffs or other products shall be prohibited by suggesting that:
1) they have an action such as psychotropic substances or narcotic drugs or
2) their use, even misused, may cause effects such as the effects of the effects of psychotropic substances or narcotic drugs.
Article 21. [ Tasks of the Minister responsible for education and education] 1. The Minister for Education and Education will take into account, on the basis of programmatic education, the issue of the promotion of mental health and healthy lifestyles, taking particular account of issues relating to the prevention of drug addiction.
2. The Minister for Education and Education, in consultation with the Minister of Health, will take action to address the issue of mental health promotion and healthy lifestyles, including prevention issues. drug addiction in the curriculum of teachers and those involved in the education and teaching of children and young people in schools and other educational system institutions.
Article 22. [ The bodies required to conduct educational, educational, information and prophylactic activities] 1. The ministers responsible for education and education, health, home affairs, public administration, transport, the Minister of National Defence and the Minister of Justice, each with regard to their activities, are required to develop and support the educational and prophylactic activities undertaken to inform the public about the harmfulness of drug addiction.
2. The bodies mentioned in the mouth. 1 shall carry out educational, educational, information and prophylactic activities consisting of:
1) promotion of a healthy lifestyle;
2) support the activities of nationwide and local organisations referred to in art. 5 par. 3, as well as other social initiatives.
3. The Minister for Education and Education, in agreement with the Minister responsible for Health, will determine, by means of a regulation, the scope and forms of conduct in schools and institutions of educational, educational, educational, educational, information and prevention, with a view to the well-being of children and young people.
Article 23. [ Scientific Units] 1. The ministers responsible for health, higher education, public finance, home affairs, transport, labour, science, the Minister of Justice and the Minister of National Defence create the conditions for conducting scientific research on the issue of the problems drug addiction and epidemiological studies.
2. Scientific units carrying out scientific research tasks on drug addiction problems, if necessary for the conduct of such research, may hold, store and purchase narcotic drugs, substances psychotropic substances, their preparations, precursors of category 1, after authorisation, as referred to in Article 35 par. 1 points 2 and 3 and paragraph. 2.
3. The scientific units referred to in paragraph. 2, they may hold, store and purchase replacement or new psychoactive substances after the notification referred to in Article 4. 24 1 paragraph 1 point 2.
Article 24. [ The implementation of tasks related to drug addiction.] 1. The Ministers responsible for health, education and education, internal affairs, public administration, public finance, transport, work and the Minister of National Defence and the Minister of Justice shall ensure that the necessary number is prepared. persons to carry out the tasks referred to in art. 2. 1.
2. The organisational units of the government administration, the organizational units of the Prison Service, the Military Gendarmerie and the higher education institutions conducting the training of the persons referred to in the paragraph. 1, may possess, store and acquire narcotic drugs, psychotropic substances, their preparations, category 1 precursors, replacement agents or new psychoactive substances, in the amount necessary to carry out this training.
3. (repealed).
4. The entities referred to in paragraph. 2, and the scientific units shall hold, store and purchase the measures, substances and preparations referred to in paragraph 2. 2 if they carry out their research to identify and confirm the commission of a criminal offence or to violate the prohibition laid down in the Article. 44b (b) 1 point 1 or 2.
5. (repealed).
6. (repealed).
Article 24 1 . [ Notification of the conduct of studies to relevant entities] 1. Conduct of the research referred to in art. 23 (1) 2 and Art. 24 ust. 4, shall be notified before they are started, in paper or in electronic form, to:
1) the provincial Pharmaceutical Inspector-in the case of narcotic drugs, psychotropic substances, their preparations, precursors of category 1, or
2) state provincial health inspector or state health inspector of the Ministry of the Interior-in the case of replacement or new psychoactive substances
-due to the seat of the scientific unit or the body carrying out the test.
2. Scientific units and entities referred to in art. 23 (1) 2 and Art. 24 ust. 2 and 4, are required to:
1) the acquisition of narcotic drugs, psychotropic substances, their preparations, precursors of category 1, surrogate agents or new psychoactive substances from entrepreneurs holding the authorisation referred to in art. 35 par. 1, art. 36 ust. 1 or Art. 40 par. 1 and 2 point 1, or sourcing them from the organisational units of the public finance sector, scientific units or research contracting entities to identify and confirm the commission of a criminal offence or a breach of the prohibition set out in Article. 44b (b) 1 (1) or (2), in the quantity necessary to carry out the examination or training;
2) records of narcotic drugs, psychotropic substances, their preparations, precursors of category 1, surrogate agents or new psychoactive substances in an orderly manner, by the dates of their acquisition or entry into their possession, by a period of 5 years starting from the end of the calendar year of the last entry in the records;
3) the storage or possession of narcotic drugs, psychotropic substances, their preparations, precursors of category 1, surrogate agents or new psychoactive substances in a way that protects against theft or destruction and before their access to unauthorriated persons;
4) destruction of narcotic drugs, psychotropic substances, their preparations, precursors of category 1, surrogate agents or new psychoactive substances in such a way as to prevent unauthorising access to them.
3. The Minister for Health in consultation with the ministers responsible for internal affairs, public finances, higher education, science, the Minister of National Defence and the Minister of Justice will determine, by means of a regulation:
1) the manner and mode of acquisition or entry into the possession, records, storage and use of narcotic drugs, psychotropic substances, their preparations, precursors of category 1, surrogate agents or new psychoactive substances, for the purpose of carrying out the tests or training referred to in Article 23 (1) 2 and Art. 24 ust. 2 and 4, with a view to the safety of their storage and the need to establish a separate record for the product, substance or preparation concerned;
2) the manner and mode of transmission of the declarations referred to in paragraph. 1, the scope of the information transmitted and the model declarations, taking into account the need to ensure efficiency in the transmission of notifications and to guarantee the transparency and consistency of the information provided;
3) the destruction of narcotic drugs, psychotropic substances, their preparations, precursors of category 1, surrogate agents or new psychoactive substances, taking into account the need to protect these substances, substances or preparations prior to their access to unauthorising persons and to ensure the safety of those involved in their destruction.
Article 24a. [ Units authorised to have intoxicating agents] 1. Organizational units of the governmental administration and the Military Gendarmerie performing operational-reconnation activities and organisational units of the Customs Service in the performance of tasks defined by the Act of 27 August 2009. o Customs Service (Dz. U. Nr. 168, pos. 1323, with late. zm.) may be in possession of narcotic drugs, psychotropic substances or their preparations and precursors of category 1 in the amount necessary to carry out confirmatory examinations of the crime.
2. Units referred to in paragraph 1, in connection with the performance of the activities and activities referred to in this provision shall be:
1. store possessed narcotic drugs, psychotropic substances or their preparations and precursors of category 1, in a way that protects against theft and destruction;
2) destroy narcotic drugs, psychotropic substances or their preparations and precursors of category 1 in such a way as to prevent unauthorised persons from being able to access them.
3. The Council of Ministers shall determine by way of regulation, entities entitled to destroy narcotic drugs, psychotropic substances or their preparations, and precursors of category 1, obtained by means of activities and activities referred to in paragraph 1. 1, as well as the detailed arrangements and conditions for their storage and destruction, having regard to the need to safeguard those measures and substances prior to the access of third parties.
Article 24b. [ Forwarding information on people reporting for treatment] 1. Treatment and rehabilitation of dependent persons shall be required to cooperate with the Office, in particular for the collection and transmission of information to the Biuru on persons reporting for treatment due to the use of the means of narcotic, psychotropic substances, or surrogate agents.
2. The information referred to in paragraph 1. 1, contains:
1) an identifier preventing the identification of the person referred to in the paragraph. 1, consisting of the first 2 letters of the first name, the first 2 letters of the surname, the date of birth and the coded information about the patient's gender;
2) the characteristics of the socio-demographic situation of the person referred to in paragraph. 1, containing data on the place of residence, education and citizenship;
(3) the formula for the use of the substances referred to in paragraph 1. 1, containing the nature and status of the narcotic drugs used, psychotropic substances or substitution agents, the frequency of their use and the manner in which they are used;
4) the history of the use of narcotic drugs, psychotropic substances or surrogate agents, containing the age of initiation of the use of individual substances and the age of commencement of problem use;
5) information on risk behaviours that may contribute to HIV, HCV and serological status of HIV, HCV;
6) the history of treatment, including the information on the continuation and termination of treatment;
7) medical diagnosis according to the current International Classification of Disease Classification and Health Problems iCD;
(8) other information required by the protocol of the European Monitoring Centre for Drugs and Drug Addiction, other than the personal data referred to in Article 3 (2) of the European Parliament and of the Council. 27 ust. 1 of the Act of 29 August 1997. on the protection of personal data (Dz. U. of 2002. No. 101, pos. 926, with late. zm.).
3. The Minister of Health shall determine, by means of a regulation, the scope and mode of cooperation with the Office of Medicinal Substances for the treatment or rehabilitation of persons using narcotic drugs, psychotropic substances or measures to replace, collect, store and process the information referred to in paragraph 1. 1, the mode of transmission and the model of an individual reporting questionnaire of a person reporting to treatment due to the use of narcotic drugs, psychotropic substances or surrogate measures, taking into account the need to protect the privacy of the persons referred to in paragraph. 1.
Chapter 4
Dealing with addicts
Article 25. [ Voluntary treatment, rehabilitation or reintegration of addicts] Taking the treatment, rehabilitation or reintegration of addicts is voluntary, if the provisions of the Act do not otherwise provide.
Article 26. [ Treatment, rehabilitation, reintegration] 1. Treatment of an addictive person leads a medical subject or a doctor performing a profession in the course of a professional practice.
2. Rehabilitation of an addicted person may lead:
1) a doctor with a specialization in psychiatry;
2) a person holding a certificate of addiction therapy specialist.
3. In the rehabilitation of an addict person may be attended by a person holding a certificate of addiction therapy instructor.
4. Reintegration of the addicts can lead to social integration centers, created on the basis of social employment regulations, and the entities mentioned in the mouth. 1 and 2 and in art. 5 par. 3.
5. For the benefits referred to in paragraph. 1-4, granted to a person dependent on his or her place of residence in the country shall not be charged on that person's charge.
Article 27. [ Certificates of specialist addiction therapy and addiction therapy instructor] 1. Certificates referred to in art. 26 par. 2 and 3, shall be issued to persons who have completed their training in the field of addiction, in accordance with the programme chosen by means of a competition held by the Office at least once per calendar year.
2. The competition offers, submitted to the Office, shall contain the following data:
1. the name and place of residence and address or name (company), seat and address of the seat of the tenderer;
2) the organizational and legal form of the bidder;
(3) the registration number of the tenderer in the business register, the records of the business activity or other relevant register;
4) the place of conducting the training;
5) planned dates of commencments and completion of the training;
6) the training programme.
3. The operator of the training shall be obliged to provide:
1) the teaching staff of the qualifications appropriate for the proper conduct of the training;
2) suitable for the implementation of the curriculum of the teaching base;
3) having an internal system for assessing the quality of education, taking into account the tools for assessing the quality of education and the method of assessment.
4. The offers shall be considered by the competition committee issued by the Director of the Office.
5. The training referred to in paragraph. 1, shall end with an examination organised by the Bureau at least twice a year.
6. The final exam consists of a written part and an oral part.
7. The certificate of addiction therapy specialist may receive the person who graduated from higher education.
8. A certificate of addiction therapy instructor may be given a person with an education of at least averages.
8a. Persons applying for the receipt of the certificates referred to in art. 26 par. Article 2 (2) and (2) 3, are obliged, under the rigorous need to retake the training, to take the examination within a period of not more than 4 years from the moment of commencation of the training.
9. Persons who have completed the training referred to in paragraph. 1, and have obtained the certificate of addiction therapy instructor and within 3 years of completion of this training have met the requirements referred to in paragraph. 7, may take the exam in the field of addiction therapy specialist without having to participate in the training, however, not later than in the period of the year after obtaining the master's degree.
10. The costs of training referred to in paragraph. 1, the examination and issue of the certificate shall be borne by the participant of that training
11. The bureau shall keep records of the certificates issued.
(12) The Minister responsible for Health shall determine, by way of regulation, the procedure for the submission of tenders, the criteria for their evaluation and the dates of the competition proceedings referred to in paragraph 1. 1, taking into account the need for the highest level of training.
13. The Minister for Health shall determine, by means of a regulation:
1) the requirements to be met by entities providing training courses in the field of addiction,
2) framework training programmes in the field of addiction,
3) mode and method of conducting the exam,
4) the composition of the examination board carrying out the examination,
5) certificate patterns: addiction therapy instructor and addiction therapy specialist
-having regard to the need for the highest level of training and the type of training
Article 27a. [ Application for training in the field of addiction] 1. The Director of the Office may subsidise the costs of training in the field of addiction to his participants, at their request, made through the entity conducting the training in the field of addiction, if these persons are employed in the units of the presenters rehabilitation, including in particular those referred to in Article 86.
2. The Director of the Office shall indicate the time limit for the submission of the applications referred to in paragraph. 1, and also fixes annually the maximum amount of funding per participant in the field of addiction training and the number of persons covered by the funding, with a view to the amount of the resources foreseen for this purpose in the plan Financial
3. The data referred to in paragraph. 2, the Director of the Office shall include, as soon as it is established, on the website of the Office's public information bulletin.
4. The application referred to in paragraph 1. 1, contains:
1. first name and surname;
2. address of the place of residence;
3) deadlines for starting and completing the training in the field of addiction;
4) justification of the request.
5. The grant of the costs of training in the field of addiction shall decide, subject to paragraph. 1, the order of the impact of the applications referred to in paragraph. 1, to the exhaustion of the appropriations provided for this purpose in the financial plan of the Office.
Article 28. [ Substitutional Treatment] 1. The dependent person can be treated with the use of substitution therapy.
2. The substitution treatment may lead the medicinal entity after obtaining the consent of the Marshal of the competent voivodship due to its registered office, issued after obtaining a positive opinion of the Director of the Office regarding compliance with the requirements specified in provisions issued on the basis of the paragraph. 7.
3. Permit of substitution treatment in medicinal entities for persons deprived of liberty shall issue the Director General of the Prison Service after obtaining a positive opinion of the Director of the Office.
4. A permit for substitution treatment may be granted to a medicinal product which has:
1) a hospital pharmacy or has entered into an agreement with an pharmacy or a pharmaceutical wholesaler in the scope of supply in a substitutional measure;
2. premises adapted to:
(a) the issuing of a substitutional measure
(b) conducting group therapy,
(c) the work of a doctor, a therapist and a social worker,
(d) sampling for analysis,
(e) the storage and preparation of substitution measures in such a way as to prevent the access of unauthorised persons;
(3) appropriate staff conditions ensuring the implementation of the outpatient programme for the programme manager in particular, and trained in the programme of nurses and support staff.
5. The permits referred to in paragraph. 2 and 3, shall be issued by administrative decision.
6. A permit for substitution treatment shall be withdrawn if the medicinal product no longer complies with the conditions under which the authorisation is granted.
6a. In order to exclude the participation of the patient at the same time in more than one programme of substitution treatment, the Office shall conduct the Central List of Subjects Covered By Substitution Treatment.
(6) A medicinal product providing substitutional treatment shall be required to provide information on the qualification, exclusion or termination of the patient ' s participation in the programme without delay to the Biuru.
(7) The Minister responsible for Health will determine, by regulation, a detailed procedure for substitution treatment, the specific conditions to be met by a medicinal product for substitution treatment, and a detailed procedure for the treatment of substitutable treatment. the collection, storage and transmission of the information referred to in paragraph 1. 6b, with a view to the well-being of addicts, including the need to maintain the anonymity of persons whose data are placed in the Central List of Subjects Covered By Substitution Treatment.
Article 29. [ Individuals subject to correctional facilities and shelters for minors] 1. In correctional facilities and shelters for minors and the organisational units of the Prison Service, treatment, rehabilitation and reintegration of the addicts placed in these establishments is carried out.
2. The Minister of Justice in consultation with the Minister of Health competent for health shall determine, by regulation, the detailed conditions and procedure of the therapeutic, rehabilitation and reintegration course in relation to the addicts, placed in:
1) correctional facilities and shelters for minors,
2. organisational units of the Prison Service
-having regard to the welfare of the persons present in those units.
Article 30. [ Compulsory treatment and rehabilitation] 1. At the request of a statutory representative, relatives in a straight line, sibling or actual guardian or from the office of a family court may direct the underage person dependent on forced treatment and rehabilitation.
2. The time of compulsory treatment and rehabilitation shall not be determined in advance, however, it shall not be longer than 2 years.
3. If the dependent person is 18 years old, before the completion of the compulsory treatment or rehabilitation, the family court may prolong them for the time necessary to achieve the purpose of treatment or rehabilitation, altogether not longer than the specified in the paragraph. 2.
4. Proceedings in the cases referred to in paragraph. 1, shall be held in accordance with the provisions on the proceedings in the cases of minors.
Chapter 5
Precursors, narcotic drugs, psychotropic substances, replacement agents and new psychoactive substances
Article 31. [ Breakdown of intoxicants] 1. The intoxicants shall be divided into groups according to the degree of risk of addiction when used for purposes other than medical purposes and the scope of their use for medical purposes.
2. The division of intoxicants into groups I-N, II-N, III-N and IV-N defines Annex no. 1 to the Act.
Article 32. [ Breakdown of psychotropic substances] 1. The psychotropic substances shall be divided into groups according to the degree of risk of addiction when used for purposes other than medical purposes and the scope of their use for medical purposes.
2. The division of psychotropic substances into groups I-P, II-P, III-P and IV-P defines Annex no 2 to the Act.
Article 33. [ Narcotic drugs, psychotropic substances used for medical purposes] 1. Intoxicating agents of I-N and II-N groups and psychotropic substances of II-P, III-P and IV-P groups may be used only for medical, industrial or conducting research purposes.
2. The psychotropic substances of the I-P group may only be used for the purpose of carrying out the tests, and the intoxicating agents of the IV-N group for the sole purpose of carrying out the tests and in the medical treatment of animals-within the scope indicated in Annex No. 1 to the Act.
Article 34. [ Authorised to have narcotic drugs, psychotropic substances] 1. Drugs, psychotropic substances or preparations thereof, and precursors of category 1 may only be provided by an entrepreneur, an organisational unit or a natural person entitled under the provisions of the Act, of Regulation 273/2004 or Regulation 111/2005.
2. Owned by narcotic drugs, psychotropic substances or their preparations and precursors of category 1 shall be subject to security by law enforcement or by the customs authorities in accordance with the procedure laid down in the criminal proceedings.
3. In the event that no criminal proceedings have been initiated, the forfeiture of the Treasury of intoxicants, psychotropic substances or their preparations and the precursors of category 1 adjudication of the court on the request of the provincial inspector The pharmaceutical or the Chief Pharmaceutical Inspector of the Polish Army.
4. In the case of a judgment by the court of forfeiture to the Treasury of the State of intoxicants, psychotropic substances or their preparations and the precursors of category 1, they shall be destroyed. The Tribunal may decide upon the application of the units referred to in Article 24 ust. 2 and 4, forfeiture to the Treasury of narcotic drugs, psychotropic substances or their preparations and precursors of category 1, by transferring them in whole or in part to those units.
5. (repealed).
Article 35. [ Manufacturing, processing or reprocessing of narcotic drugs or psychotropic substances] 1. Permit of the Chief Pharmaceutical Inspector requires the taking of activities in the scope of:
1) the manufacture, processing, processing, import or distribution of narcotic drugs or psychotropic substances;
2. the manufacture, processing, processing, import, distribution or use for scientific research purposes, in the scope of its statutory activities, precursors of category 1;
3) the manufacture, processing, processing for the purpose of conducting scientific research, by scientific units in the scope of its statutory activities, narcotic drugs of groups I-N, II-N and IV-N or psychotropic substances of I-P, II-P, III-P and IV-P. groups
2. Use for conducting scientific research, by scientific units in the scope of its statutory activities, narcotic drugs or psychotropic substances requires the permission of the provincial Pharmaceutical Inspector.
3. It does not require the authorisation of interruptions of narcotic drugs, psychotropic substances and precursors, if carried out at the pharmacy under the principles laid down in the Act of 6 September 2001. -Pharmaceutical law.
4. The permits referred to in paragraph. 1 and 2, it appears:
1) after the statement, by the inspector for the production of the Chief Pharmaceutical Inspectorate, that the entrepreneur holding the permit referred to in art. 38 par. 1 of the Act of 6 September 2001. -Pharmaceutical law, or entered in the register referred to in Article 5b (b) 1 of this Act, fulfils the conditions laid down in the Act, and in the case of precursors of category 1 also the conditions laid down by the provisions of Regulation 273/2004, Regulation 111/2005 and Commission Regulation (EC) No 1277/2005 of 27 July 2005. laying down implementing rules for Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and of Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade in drug precursors between the Community and third countries (Dz. Urz. EU L 202 of 03.08.2005, p. 7);
2) after the statement by the provincial pharmaceutical inspector that the entrepreneur, other than the one referred to in point 1, applying for the issue of the permit meets the conditions laid down by the provisions of the Act, and in the case of precursors of category 1 also the conditions the provisions laid down in Regulation (EC) No 273/2004, Regulation (EC) No 111/2005 and Commission Regulation (EC) No 1277/2005 of 27 July 2005. laying down implementing rules for Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and of Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade in drug precursors between the Community and third countries.
5. The permits referred to in paragraph. 1 and 2, specify the permitted size and purpose of the manufacture, processing, processing, import, distribution, or use of narcotic drugs, psychotropic substances or precursors of category 1.
6. Entrepreneurs referred to in paragraph. 4, are required:
1) keep records of narcotic drugs, psychotropic substances or precursors of category 1;
2) store possessed narcotic drugs, psychotropic substances or precursors of category 1 in a way that protects against theft or destruction, including during their transportation.
7. The Minister responsible for health shall determine, by means of a regulation:
1. the specific conditions and mode of issue and the withdrawal of the authorisations referred to in paragraph 1. 1 and 2, including the qualification requirements of the person responsible for the supervision of the manufacture, processing, processing, import, distribution, marketing or use for the purpose of conducting scientific research in intoxicating agents, psychotropic substances or precursors of category 1, with a view to ensuring the correct safeguards against the use of narcotic drugs or psychotropic substances authorised by unauthorised persons or for purposes other than those of specified in the permit issued;
2) models of applications for authorization for the manufacture, processing, processing, import, distribution, marketing or use for the purpose of carrying out scientific research of narcotic drugs, psychotropic substances or precursors of category 1, taking into account the attention and transparency of the proceedings;
3. the conditions and means of issuing narcotic drugs, psychotropic substances or precursors of category 1 and the records of the manufacture, processing, processing, import, distribution, marketing or use for the purpose of carrying out scientific research narcotic drugs, psychotropic substances or precursors of category 1, bearing in mind the safety of storage and the need to develop separate records for a given measure, substance or precursor.
Article 36. [ Collection of poppy milk and opium from poppy and herb or resins of hemp other than non-wovens] 1. A collection of poppy milk and opium from poppy seeds and herb or resin of hemp other than non-wovens is allowed only for the purpose of conducting scientific research, after obtaining the permission of the Chief Pharmaceutical Inspector.
2. The preparation of extracts from the manic straw may take place only in the entrepreneur and in the scientific unit and the Central Centre for the Study of Varieties of Plant Varieties-in the scope of their statutory activities, after obtaining the permission of the Chief Inspector Pharmaceutical
3. The Minister responsible for health shall determine, by means of a regulation, the conditions and the mode of issue and withdrawal of the authorisations referred to in paragraph 1. In view of the principle of respect for the rights of the applicant and to ensure the efficiency of the proceedings, the content of the application for these authorisations and the content of the application for such authorisations.
Article 37. [ Parties authorised to trade narcotic drugs or psychotropic substances] (1) Imports, exports, intra-Community supply or intra-Community acquisitions of narcotic drugs or psychotropic substances may be made by operators holding the authorisations referred to in Article 3. 35 par. 1 point 1 or art. 40 par. 1, after obtaining the permission of the Chief Pharmaceutical Inspector laying out the measures or substances which may be the subject of import, export, intra-Community supply or intra-Community acquisitions.
2. Imports or intra-Community acquisitions of narcotic drugs or psychotropic substances may be carried out by scientific units referred to in art. 35 par. 1 point 3 and paragraph. 2, after obtaining the permission of the Chief Pharmaceutical Inspector laying out the measures or substances which may be the subject of import or intra-Community acquisitions.
3. Imports or intra-Community acquisitions of narcotic drugs or psychotropic substances may occur after obtaining, for each consignment imported into the territory of the Republic of Poland:
1. import licences, or intra-Community acquisitions, issued by the Chief Pharmaceutical Inspector, and
(2) the export licence or intra-Community supply issued by the competent authorities of the exporting country.
4. The export or intra-Community supply of narcotic drugs or psychotropic substances may occur after obtaining, for each consignment exported from the territory of the Republic of Poland, export licences or intra-Community supplies, issued by the Chief Pharmaceutical Inspector on the basis of an import licence or intra-Community acquisitions issued by the competent authorities of the importing country.
(5) Imports, exports, intra-Community supply or intra-Community acquisitions of manic straw may only be made by the traders referred to in Article 3. 35 par. 1 point 1 or art. 40 par. 1, after obtaining the licences provided for in paragraph. 3 and 4.
6. The carriage through the territory of the Republic of Poland of narcotic drugs, psychotropic substances and poppy straw shall be permitted on the basis of an export licence issued by the competent authorities of the exporting country for each consignment.
7. In the cases referred to in paragraph. 3-6, export licences or intra-Community delivery shall be attached to each consignment.
(8) Imports of intoxicants into the customs warehouse are prohibited.
9. Imports of narcotic drugs, psychotropic substances into free zones shall be prohibited.
(10) Imports, exports, intra-Community supply or intra-Community acquisitions of narcotic drugs, psychotropic substances or precursors of category 1 for their own medical needs may be carried out on the basis of the documents referred to in the legislation. issued on the basis of the paragraph 12.
11. Import, export, intra-Community supply or intra-Community acquisitions of narcotic drugs and psychotropic substances which are stocks of the organisational units of the Ministry of National Defence taking part in missions, exercises or trainings outside the country grants the Supreme Pharmaceutical Inspector of the Polish Army at the request of the manager (commander, commandant, chief) of the organizational unit.
(12) The Minister responsible for Health shall determine, by means of a regulation, the specific conditions and the procedures for issuing the licences and documents referred to in paragraph 1. 3, 4 and 10, the models of those licences and documents, the obligations of the entities and persons holding those licences and the documents concerning the storage of the appropriations covered by the authorisation, the issuing of those funds to the authorized body and the keeping of records in the field of their possession and marketing, having regard to the efficiency of the handling of the authorisation.
Article 38. [ Chief Pharmaceutical Inspector] 1. Entrepreneurs operating in the manufacturing, processing, processing, import, export, intra-Community supply or intra-Community acquisitions and wholesale trade of category 1 and 4 wholesale precursors shall be provided by the Chief Inspector. Pharmaceutical information on any suspicion of compliance with the provisions of the law:
1) orders for these substances;
2) activities involving those substances;
3) attempts to use these substances.
2. The provisions of the paragraph. 1 shall also apply to the precursors of categories 2 and 3, except that the information referred to in those provisions shall be provided to the General Sanitary Inspector.
3. The Chief Pharmaceutical Inspector with regard to the precursors of category 1 and 4, and the Chief Sanitary Inspector for the precursors of category 2 and 3, in justified cases shall notify the Police, the Border Guard and the Customs Service organs of the need to stop the consignment of precursors that does not meet the requirements laid down in the law.
4. The Chief Pharmaceutical Inspector and the Chief Sanitary Inspector keep records of the information obtained in the mouth mode. 1 and 2.
5. The Minister for Health, in agreement with the Minister responsible for public finance and the Minister for Internal Affairs, shall determine by way of regulation:
1) a detailed way of conveing information,
2) how to keep records of information obtained in the mouth mode. 1 and 2,
3. the detailed mode and manner of notification referred to in paragraph. 3, as well as the model of such notification,
4. the mode and method of proceeding with the consignment referred to in paragraph. 3-having regard to the prevention of the illicit manufacture of precursors.
Article 39. [ Permit for the marketing of narcotic drugs, psychotropic substances] 1. The permits referred to in art. 35 par. 1 and 2, art. 36 ust. 1 and 2, art. 40 par. 1 and 2 and Art. 49 (1) 1, and of the licences referred to in Article 37 par. 1-6, shall be granted at the request of the applicant for a period of time marked or unmarked for a period of time.
2. Before taking a decision on the issue of an authorisation or authorisation, the issuing authority or the authorisation, hereinafter referred to as the "authorisation authority", may:
1) to call on the applicant to complete, within the prescribed period, missing documentation certifying that he meets the conditions laid down by the provisions of the Act;
2. carry out a review of the facts as given in the application for authorisation or of the authorisation in order to determine whether the applicant fulfils the conditions for the exercise of the authorised activity or the licence.
3. The allocation of an authorisation or permit, amendment of an authorisation or authorisation, refusal of authorisation or authorisation, and the withdrawal of an authorisation or authorisation shall be made by decision. The decision to withdraw the licence or permit shall be immediately executed.
4. The authorising authority shall, in the event of a claim, that the holder of the authorisation or of the authorisation shall act in a manner which does not comply with the provisions of the law governing the activity covered by the licence or licence, shall immediately set a time limit for the authorisation of the licence or licence. to remedy these irregularities.
5. The authorising authority shall withdraw the authorisation or authorisation, where:
1) an entity to which an authorisation or permit has been granted no longer fulfils the conditions required for the performance of the activity specified in the authorisation or the licence;
2. the entity referred to in point 1 has not removed, in the authority designated by the authorising authority, any actual or legal status which is not in conformity with the provisions of the law governing the activity covered by the permit or permit.
6. The holder of the authorisation or of the authorisation shall notify the authority of any alteration of the data specified in the authorisation or of the licence.
7. An entity that has been withdrawn from the grounds referred to in paragraph 1. 5, may again apply for an authorisation to the same extent not earlier than 3 years from the date of issue of the decision to withdraw the permit.
(8) For the submission of an application for an authorisation for the manufacture, processing, processing, distribution, wholesale trade, cultivation, harvesting or testing and import licences, exports, intra-Community acquisitions and intra-Community supply of measures narcotic, psychotropic substances and precursors of category 1 and 4, as well as the modification of these permits or permits, shall be collected fees which constitute the revenue of the state budget.
9. The fees referred to in paragraph. 8, shall be submitted to the account of the current authorising authority at the level of:
1) 750 zł-for filing an application for a permit for wholesale trading, distribution, manufacture, processing, processing or use for the testing of narcotic drugs, psychotropic substances or precursors of category 1;
2) 750 zł-for filing an application for authorisation of a collection of poppy milk and opium with poppy seeds and herb or resin of hemp other than non-fibrous;
3) 750 zł-for filing an application for the permit for the cultivation of poppy and hemp carried out by the scientific unit and the Central Centre for the Research of Varieties of crops;
4) 350 zł-for filing an application for a change of consent, referred to in points 1-3;
5) 100 zł-for the submission of an application for an import licence, export, intra-Community acquisition or intra-Community supply of narcotic drugs or psychotropic substances;
6) 100 zł-for the submission of an application for the export permit for the export of category 4 precursors;
7) 100 zł-for submitting an application for an import licence or export of category 1 precursors;
8) 50 zł-for filing an application for a change of permit or permit referred to in points 5 to 7.
10. The application referred to in paragraph 1. 8, shall be accompanied by proof of payment of the fee. In the absence of proof of payment of the fee, the application shall be left without consideration.
Article 40. [ Wholesale of narcotic narcotic drugs or psychotropic substances] 1. The Permit of the Chief Pharmaceutical Inspector requires the circulation of wholesale narcotic drugs or psychotropic substances.
2. The Chief Pharmaceutical Inspector at the request of the entrepreneur shall issue:
1. the authorisation for the wholesale trade in precursors of category 1, in accordance with the provisions of Regulation (EC) No 273/2004, Regulation 111/2005 and Commission Regulation (EC) No 1277/2005 of 27 July 2005. laying down implementing rules for Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and of Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade in drug precursors between the Community and third countries;
2) permit to export category 4 precursors, in accordance with the provisions of Regulation 111/2005;
(3) simplified authorisation for the export of category 4 precursors, in accordance with European Union rules laying down rules for the supervision of trade in drug precursors between the Community and third countries, if this does not result in illegal risk the use of category 4 precursors.
3. Entrepreneurs referred to in paragraph. 2, are required:
1) keep records of narcotic drugs, psychotropic substances or precursors of category 1;
2) store possessed narcotic drugs, psychotropic substances or precursors of category 1 in a way that protects against theft or destruction, including during their transportation.
4. The permits referred to in paragraph. 1 and paragraph. In point 1, the following shall be issued after the statement:
1) by the inspector for the wholesale trading of the Chief Pharmaceutical Inspectorate, that the entrepreneur holding the permit referred to in art. 76 (1) 1 of the Act of 6 September 2001. -Pharmaceutical law, meets the conditions laid down by law;
2) by the voivodship of the Pharmaceutical Inspector, that the entrepreneur, other than the one specified in point 1, applying for the issue of the permit meets the conditions laid down by the provisions of the Act.
5. The Minister responsible for health shall determine, by means of a regulation:
1. the specific conditions and mode of issue and the withdrawal of the authorisations referred to in paragraph 1. 1, including the qualification requirements to which the person responsible for the supervision of the marketing of narcotic drugs, psychotropic substances or precursors of category 1 should be responsible, with a view to ensuring that the correct safeguards are ensured before the use of narcotic drugs, psychotropic substances or precursors of category 1, authorised by unauthorised persons or for purposes other than those specified in the authorisation granted;
2) models of applications for authorisation to place the marketing of narcotic drugs, psychotropic substances or precursors of category 1, taking into account the efficiency and transparency of the proceedings;
3) the conditions and means of issuing narcotic drugs, psychotropic substances or precursors of category 1 and the records of the marketing of narcotic drugs, psychotropic substances or precursors of category 1, with a view to safety the storage and the need to compile separate records for the product, substance or precursor.
Article 41. [ Retailing with narcotic drugs, psychotropic substances] 1. The retail turnover of narcotic drugs, psychotropic substances and precursors which are medicinal products shall carry out pharmacies and pharmacy points, providing appropriate conditions for their storage, preventing the access of persons not entitled to these measures and substances.
2. Preparations containing narcotic drugs or psychotropic substances shall be issued from the pharmacy solely on the basis of a specially marked prescription or a demand, subject to paragraph. 4.
3. To the entities referred to in paragraph. 1, Article shall apply. 40 par. 3.
4. Preparations containing narcotic drugs of the II-N group or psychotropic substances of III-P and IV-P groups may be issued from the pharmacy on the basis of prescriptions other than those referred to in the paragraph. 2, and preparations containing intoxicating agents of III-N group may be issued from pharmacies without a prescription.
5. The Minister responsible for health shall determine, by means of a regulation:
1. detailed conditions of storage by pharmacies of narcotic drugs, psychotropic substances, precursors of category 1 and preparations containing these substances or substances and the way of record-keeping in their possession and marketing, Having regard to the security of these substances against access to third
2. detailed conditions for issuing prescriptions and requisitions for preparations containing narcotic drugs or psychotropic substances, formulae of these documents and the issue of these preparations from pharmacies, taking into account the conditions for the safety of the distribution of preparations.
Article 42. [ Entities with medicinal products containing narcotic drugs or psychotropic substances] 1. The medicinal product, which-in accordance with the provisions of the Act of 6 September 2001 -Pharmaceutical law-did not create a hospital pharmacy or a hospital pharmacy department, an animal medical facility and a doctor, a dentist or a veterinarian, who performs a profession in the course of a professional practice, as well as another entity the activity requires the possession and use for medical purposes of preparations containing narcotic drugs of groups I to N, II-N, III-N and IV-N or psychotropic substances of groups II-P, III-P and IV-P, have and apply these preparations if they are authorised for marketing as medicinal products on the basis of pharmaceutical legislation and after obtaining the approval of the Provincial Pharmaceutical Inspector.
2. The medicinal product, which-in accordance with the provisions of the Act of 6 September 2001 -Pharmaceutical law-did not create a hospital pharmacy, an animal medical facility and a doctor, a dentist or a veterinarian, who practised a profession in the course of a professional practice whose activities for the purpose of clinical trials requires the possession and use of preparations containing narcotic drugs of groups I-N, II-N, III-N and IV-N or psychotropic substances of groups II-P, III-P and IV-P, have and apply these preparations after obtaining the consent of the voivodship Pharmaceutical Inspector.
3. The Provincial Pharmaceutical Inspector gives consent:
1) referred to in paragraph 1. 1-for a fixed period of not more than 3 years;
2) referred to in paragraph 1. 2-for a fixed period, not longer than that specified in the permit to conduct a clinical trial.
4. The Minister responsible for health shall determine, by means of a regulation:
1) the model of the request for consent, referred to in the paragraph. 1 and 2, taking into account the need for efficiency;
(2) the types of preparations containing narcotic drugs and psychotropic substances which may be held for medical purposes or used for clinical trials, together with an indication of their quantity and the group to which they are qualified, taking into account the need for their proper identification;
(3) conditions for the supply and storage of preparations containing narcotic drugs and psychotropic substances held for medical purposes or for use in clinical trials, taking into account the need to protect those substances from the wrong use;
4) the types of entities the activity of which requires the possession and use of preparations containing narcotic drugs and psychotropic substances and the manner in which those bodies of dossiers carry out the documentation, having regard to the safety of storage and the need to develop separate documentation for the product or substance concerned.
Article 43. [ Report on the activity specified in the authorisation or licence] 1. Entrepreneur and other organizational unit who have obtained the permits referred to in art. 35 par. 1 and 2 or art. 40 par. 1 and 2, or of the licences referred to in Article 37 par. 3-5, shall be required to submit to the Chief Pharmaceutical Inspectorate the activity reports specified in the permit or permit.
2. The Minister responsible for health shall determine, by means of the Regulation, the detailed conditions, modus and timing of the reports referred to in paragraph 1. 1, taking into account the necessary data to be included.
Article 44. [ Supervision of proceedings with narcotic drugs, psychotropic substances] 1. Supervision of the crops referred to in art. 49 (1) 1, manufacture, process, import, distribute, rotate and destroy or use for the purposes of scientific research of narcotic drugs, psychotropic substances and precursors of category 1 shall be exercised by the voivodship inspector pharmaceutical competent due to the establishment of the entrepreneur or scientific entity-through the control of the implementation of obligations under Regulation 273/2004, Regulation 111/2005 and the provisions of the Act, with the exclusion of the entrepreneurs referred to in paragraph 2a.
2. Supervision of precursors of category 2 and 3 shall exercise the state district health inspector due to the registered office of the manufacturer, importer or other marketing entity-through the control of the implementation of the obligations imposed on the manufacturer, the importer or any other entity placing on the market resulting from the Act, Regulation 273/2004 and Regulation 111/2005 and issuing the permits-on the basis and in accordance with the procedure laid down in the regulations on the State Sanitary Inspection, Regulation 273/2004 and Regulation 111/2005.
2a. The Chief Pharmaceutical Inspector exercises supervision over:
1. the manufacture, processing, processing, import, distribution and destruction of narcotic drugs, psychotropic substances and precursors of category 1 by an undertaking authorised in accordance with Article 3 (1) of Regulation (EC) No matter. 38 par. 1 of the Act of 6 September 2001. -Pharmaceutical law, or an entrepreneur entered in the register referred to in art. 5b (b) 1 of this Act-implemented in the framework of checks on compliance with the obligations arising from the provisions of Regulation 273/2004 and Regulation 111/2005 and the provisions of the Act;
2. the wholesale trade in narcotic drugs, psychotropic substances or precursors of category 1 by an undertaking authorised in accordance with Article 4 (1) of the EC Convention. 76 (1) 1 of the Act of 6 September 2001. -Pharmaceutical law-implemented under the control of compliance with the obligations arising from the provisions of Regulation (EC) No 273/2004 and Regulation 111/2005 and the provisions of the Act;
3. the export of category 4 precursors by the authorised economic operator referred to in Article 4 (3). 38 par. 1 or in Art. 76 (1) 1 of the Act of 6 September 2001. -Pharmaceutical law-implemented as part of the control of compliance with the obligations arising from the provisions of Regulation 111/2005 and the provisions of the Act.
3. The competent authority for third countries with notification prior to export in the field of precursors of category 2 and category 3, referred to in Article 3. 11 (1) 1 and 2 of Regulation 111/2005, is the Chief Sanitary Inspector.
4. The tasks for making the registration referred to in art. 3 para. Article 6 of Regulation (EC) No 273/2004, including the holding of a national register of economic operators and users who have been granted registration, shall be carried out by the Inspector for Chemical Substances. The granting, refusal, suspension or cancellation of registration shall be made by decision. The Inspector for Chemical Substances shall notify the competent State Sanitary Inspector of the decision of the decision.
5. The Minister responsible for health shall provide the European Commission with the information referred to in Article 4. Articles 13 and 16 of Regulation (EC) No 273/2004 and Articles (Article 32 of Regulation 111/2005)
6. The Minister of National Defence exercises supervision over the processing, storage, turnover and stockpiles of narcotic drugs and psychotropic substances in the subordinate organisational units-on the basis and in the manner prescribed by the regulations in question. in paragraph 1 and 2.
7. The Minister responsible for internal affairs shall exercise supervision over the processing, storage, turnover and stocks of precursors of category 2 and 3 group in subordinate organisational units-on the basis and in the mode specified in the regulations referred to in paragraph 2.
8. Entities which, in the course of their activity, have broken, falsified narcotic drugs, psychotropic substances or precursors of category 1, their mixtures, also as ingredients of medicinal products or which have expired, destroy those substances in the manner laid down in the Regulation referred to in paragraph 1. 9.
9. The Minister of Health shall determine, by means of a regulation, detailed conditions and procedures for the treatment of narcotic drugs, psychotropic substances and precursors of category 1, their mixtures or wastes, medicinal products, broken, falsified or expired, containing narcotic drugs, psychotropic substances or precursors of category 1 in its composition, taking into account, in particular, the requirements of the protection against misuse, methods the destruction of these measures according to their type and quantity and the entities concerned required to cover the costs associated with the destruction of these measures.
Article 44a. [ Application of the provisions of the Act on the freedom of economic activity] For the control of the economic activities of the entrepreneur referred to in art. 35, 36 and 40, the provisions of Chapter 5 of the Law of 2 July 2004 shall apply. about the freedom of economic activity (Dz. U. of 2010 No. 220, item. 1447, as of late. zm.).
Article 44b. [ Prohibition of the manufacture, import and placing on the market of surrogates and new psychoactive substances] 1. The manufacture, import and placing on the market of the territory of the Republic of Poland shall be prohibited:
(1) replacement measures;
2) new psychoactive substances.
2. The Minister of Health shall determine, by means of a regulation, a list of new psychoactive substances covering these substances or their groups, taking into account the effects of these substances on human health or human life or the possibility of causing damage Social
Article 44c. [ Decision on the suspension of the manufacture or withdrawal of the product from the market] 1. Where the manufacturing or placing on the market of a product on which there is a reasonable suspicion that it is a substitute agent or a new psychoactive substance is found to be appropriate, due to the place of manufacture or entry into the public health inspector requires, by means of a decision, to suspend the manufacture of that product or to withdraw it from the market, for the time necessary to carry out tests to determine whether he is a substitute agent or a new substance. psychoactive, however, not longer than 18 months.
2. The Chief Sanitary Inspector shall make public the information about the issuance of the decision referred to in the paragraph. 1, by the announcement on its website of the Public Information Bulletin of the name of the product, the name of the manufacturer, the type of packaging and its size.
3. In the case of the decision referred to in the paragraph. 1, the competent State Sanitary Inspector:
1) make a security of the product on which there is a reasonable suspicion that it is a substitute agent or a new psychoactive substance;
2) require the cessation of operations in the premises or facilities for the manufacture or entry of that product on the market, for the time necessary to remove the hazard, not longer than 3 months.
4. State sanitary inspector competent in respect of the place of manufacture or placing on the market of the product referred to in paragraph 1, prohibits, by means of a decision, its manufacture or placing on the market, it orders its withdrawal from the market, and also adjudicates its forfeiture to the State Treasury and destruction if that product is a replacement measure or a new substance psychoactive.
5. State sanitary inspector, who issued the decision referred to in paragraph. 4, shall be the competent authority for the destruction of the product which is the subject of that decision. The destruction shall be carried out by the committee. A destruction protocol shall be drawn up for the destruction of the product, which shall include:
1) the designation of the competent authority on the destruction;
2) the composition of the committee set up for destruction;
3) the designation of the decision as the basis for destruction
4) the nature of the destroyed product, its name and quantity;
5) information about the method of destruction used;
6) determination of the place and time of destruction;
7) the signatures of the members of the committee.
6. Costs of the conduct of the proceedings and research referred to in paragraph 1, as a result of which the product under examination referred to in paragraph 1 is found to be examined. 1, is a replacement measure or a new psychoactive substance, and the costs of destruction of this product shall be borne by the party to the proceedings.
7. The competent State Sanitary Inspector shall issue a decision fixing the amount of the costs referred to in paragraph 1. 6, specifying a 7-day payment deadline from the date on which the decision fixing the amount of costs has become final.
8. The security referred to in paragraph 1 Article 3 (1), and the enforcement of the claims referred to in paragraph 3 (1), 6, follow the rules on enforcement proceedings in the administration.
9. From the amount of receivables referred to in paragraph. 6, the statutory interest shall be charged, starting from the date on which the due date for their payment has expired.
10. The claims referred to in paragraph 1 6, the statute of limitations shall expire within 3 years from the date on which the decision fixing the duties has become final.
11. If, as a result of the tests referred to in paragraph 1, 1, the presence of a non-new psychoactive substance, but having an effect on the central nervous system, has been found to be notified to the Team as a result of this study.
12. Tests to determine whether or not the product referred to in paragraph (s) is concerned. 1, is a replacement measure or a new psychoactive substance, shall carry out operators, including scientific bodies, with scientific and technical preparation, technical preparation and infrastructure, to determine whether the product under examination is a means of a replacement or a new psychoactive substance, in particular the term:
1) the origin of the substance with the action on the central nervous system identified by the tests;
2. the mechanism of action of that substance;
3) its pharmacological activity;
4) side effects, including somatic and psychiatric effects in humans.
(13) The Minister responsible for Health shall determine, by means of a regulation, a list of the bodies referred to in paragraph 1. 12, with a view to ensuring the efficiency of the proceedings carried out by the bodies of the State Sanitary Inspection.
Article 44d. [ Examination, storage and destruction of a replacement product or a psychoactive substance] 1. In the case of the finding of imports into the territory of the Republic of Poland of a product for which there is a reasonable suspicion that it may be a replacement measure or a new psychoactive substance, the customs body occupies the consignment of this product on the time necessary to determine whether it is a substitute agent or a new psychoactive substance, but not longer than 18 months.
2. In the event of the need for testing of the product referred to in paragraph. 1, aimed at determining whether it is a replacement measure or a new psychoactive substance, carrying out the entities referred to in Article 44c ust. 12.
3. If, as a result of the conducted tests, it is found that the product under examination is a replacement measure or a new psychoactive substance, the Customs Service body shall request the decision of its forfeiture in favour of the State Treasury.
4. The forfeiture of a product which is a replacement measure or a new psychoactive substance in favour of the State Treasury, at the request of the customs body, the court, applying the provisions of the Code of Civil Procedure.
5. A replacement product or a new psychoactive substance, the forfeiture of which has been decided, shall be destroyed.
6. If the importing entity is unknown, the replacement product or the new psychoactive substance shall be destroyed without the need for a forfeiture in favour of the State Treasury.
(7) The costs of research, storage and destruction of a replacement product, or a new psychoactive substance, shall be borne by the importing entity. If the importing entity is unable to establish a replacement product or a new psychoactive substance, the costs of testing, storage and destruction shall be financed from the State budget, from the part of the remaining room. customs and customs offices.
Chapter 6
Cultivation of poppy and hemp
Article 45. [ Restrictions on poppy and hemp.] 1. The anointment of the poppy, with the exception of the uncomposed maku, can be conducted exclusively for the needs of the pharmaceutical industry and the seed industry.
2. The use of the uncomposed poppy maku may be carried out exclusively for food and seed purposes.
3. The cultivation of fibrous cannabis can be carried out exclusively for the needs of the textile, chemical, pulp and paper industry, food, cosmetics, pharmaceutical, building materials and seed industry.
4. The rights of hemp other than those referred to in paragraph. 3 is forbidden.
Article 46. [ Conditions of cultivation and buying-in of poppy and hemp hemp] 1. The right of poppy may be carried out on a specified surface, in demarcated areas, on the basis of a permit for cultivation, using seed of an elite category or a qualified category within the meaning of the provisions on seed, and additionally, a cultivation contract concluded with the entity holding the permission of the Marshal of the Voivodeship for carrying out activities in the scope of the poppy's buying-in.
2. The marketing of fibrous cannabis may be carried out on a certain surface, in demarcated areas, on the basis of a permit for cultivation, using seed of the basic category or the category qualified within the meaning of the provisions of In addition:
1) the cultivation contract concluded with the entity holding the permission of the Marshal of the voivodship for carrying out activities in the scope of the buying-in of fibrous hemp, or
2. the obligation to process hemp hemp in its own scope for the purposes set out in the Article. 45 par. 3, submitted to the Marshal of the Voivodship competent for the place of the crop position, within 14 days after the sowing of their sowing;
3. (repealed);
4) (repealed).
(3) The use of seed of poppy or hemp of fibrous categories or categories certified within the meaning of the provisions on seed shall be confirmed by the invoice for the purchase of that seed and the label on the packages of seed of those seed. of plants.
4. buying-in activities:
1) poppy, on the basis of the agreement referred to in paragraph. 1,
2) hemp fibre on the basis of the contract referred to in paragraph. 2 point 1
-may conduct an entity authorised by the Marshal of the Province responsible for the place where the crop is located, specifying in particular the scope and purpose of the operation.
5. The permit referred to in paragraph 5. 4, it shall be issued by decision, on request, which shall include:
1) first name, surname, determination of the place of residence and address or name (company), registered office and address of the applicant;
2) the tax identification number (NIP) of the entity or the identification number in the national official register of entities of the national economy (REGON), if it has been given, and in the case of a natural person also the serial number of the universal electronic economy the population register system (PESEL), if it has been granted;
3) address of the place of execution of the buying-in business;
4) information on the scope and purpose of the activities undertaken.
6. The application referred to in paragraph 1. 5, shall be attached:
1) a statement that the applicant has a warehouse or means of transport, protected from theft of a bag (makings) referred to in art. 48 (1) 1, or
2. (repealed);
3) the obligation to communicate on request to the Marshal of the voivodship the information concerning the scope and purpose of the conducted business.
7. The Marshal of the voivodship shall withdraw the permit in case of violation of the operating conditions specified in the Act or in the permit.
8. The Sejmik of the voivodship, after consulting the Minister responsible for health and the minister responsible for agriculture, will determine, by way of a resolution, the general area dedicated annually under the cultivation of poppy or fibrous hemp and the rejoinder of those crops, with a view to the risk of drug addiction, the demand for raw materials derived from these crops and the tradition of cultivation of poppy and hemp fibre in the area concerned.
Article 47. [ Permit for the cultivation of poppy or fibrous hemp] 1. Permission for the cultivation of poppy seeds or hemp cannabis is issued by the mayor (mayor, president of the city) due to the place where the crop is located.
2. The permit referred to in paragraph 2. 1, it shall appear, by means of a decision, on a proposal containing:
1) first name, surname, determination of the place of residence and address or name (company), registered office and address of the applicant;
2) information on the variety of poppies or hemp hemp, the area of cultivation and the number of the registration parcel in the land and building records, determined on the basis of the regulations of the geodesic and cartographic law;
3. (repealed);
4) a statement by the applicant that it has a room protected against the theft of the handbag (makings) referred to in art. 48 (1) 1;
5) a statement by the applicant that he was not punished for committing the offence referred to in art. 63 or 64, and the misconduct referred to in art. 65.
3. The permit referred to in paragraph 1. 1, specifies:
1) the entity for which they were issued;
2. the number of the authorisation;
(3) the variety of poppy seeds or hemp hemp;
4. the area of the growing of poppy or hemp of fibrous;
5) the number of the parcel referred to in paragraph. 2 (2) on which the cultivation of poppy or hemp fibre will be cultivated;
6. the term of validity;
7. date of issue of the permit.
3a. The application referred to in paragraph 1 shall be amended. 2, in the case of self-processing of hemp hemp from its own crops, an obligation to process the fibrous hemp in its own scope shall be attached to the objectives set out in the Article. 45 par. 3.
3b. The undertaking referred to in paragraph 1. 3a, contains:
1) the name, the name, the place of residence and the address or the name of the company, the seat and address of the manufacturer of the fibrous
2) the tax identification number (NIP) of the entity or the identification number in the national official register of entities of the national economy (REGON), if it has been given, and in the case of a natural person also the serial number of the universal electronic economy the population register system (PESEL), if it has been granted;
3) a concise description of the processing plant or the place of processing together with the equipment;
4. information on the types of products to be produced by the processing plant.
4. The Wójt (mayor, president of the city) refuses to issue an authorisation if the applicant does not give the warranty the proper protection of the harvesting of these crops before being used for purposes other than those specified in the Act, and in particular:
1) does not have a room protected against theft of the bag (makings) referred to in art. 48 (1) 1, or
2) he was punished for committing a crime referred to in art. 63 or 64, or
3) he was punished for committing a misdemeanor referred to in art. 65.
5. The permit shall be withdrawn in the event of a breach of the operating conditions laid down in the Act or in the permit.
6. The Wójt (mayor, president of the city) shall keep a register of permits issued.
Article 48. [ Proceeding with individual parts of the poppy] 1. The bag (s) with seeds, obtained from the cultivation of the maku for the pharmaceutical industry, together with the adjoining stem of up to 7 cm, shall be transferred in full to the operator of the poppy cultivation, under the conditions of specified in the cultivation contract. The manic straw, which is left after the separation of the bag (s) and the adjoining stems up to 7 cm in length, shall be destroyed by the leading crop in the manner prescribed by the cultivation contract.
2. The poppy seed from the cultivation of the uncomposed poppy poppy destroys the leading crop at its expense, as specified in the cultivation contract.
3. The remaining fire remnants of the poppy seed shall be destroyed in the place of cultivation, as a result of carrying out an appropriate agrotechnical operation, under the conditions laid down in the cultivation contract.
Article 49. [ The cultivation of poppy and hemp by the Central Centre for the Research of Varieties of cultivated plants] 1. Rules of the art. 45-48, with the exception of the provisions concerning the obligation to destroy manic straw and remnants of the poppy seed, shall not apply to the poppy and hemp cultivation carried out after the approval of the Chief Pharmaceutical Inspectorate by the Scientific and Central Unit The Centre for the Study of Varieties of Plant Varieties, in the framework of the statutory activities, as well as by the plant breeding operator and using non-fibrous hemp for insulation purposes, hereinafter referred to as the "applicant".
2. The permit referred to in paragraph 2. 1, it shall be issued with the following application:
1) the name and address of the applicant;
2) the data of the person responsible for ensuring proper control of the crop and its protection against the access of the unauthor-faced persons;
3) data concerning the location, type and size of the crop;
4) data on the planned research, in particular determining their purpose;
5. information on the type of scientific unit;
6) the date and signature of the person authorized by the applicant to submit the application.
3. The application referred to in paragraph. 2, shall be accompanied by:
1) the opinion of the organisational unit of the Police competent for the place of cultivation, concerning the way of securing the crop against the access of unauthoritrised persons;
2) the statutes of the applicant for the issue of an authorisation, if applicable.
Article 50. [ Supervision of the crops of poppy or hemp fibre] 1. The supervision of the crops of poppy seeds or hemp cannabis has been exercised by the mayor (mayor, president of the city) due to the place where these crops are located.
2. In the exercise of the supervision of the person authorized by the authority referred to in paragraph. 1, shall be entitled to:
1) entry into the land on which the cultivation of poppy or hemp-fibre crops is carried out, and the access to such land by other properties;
2) control of documents entitling to the production of poppy seeds or hemp cannabis;
3) requests for explanations from the operator of the poppy or hemp fibre.
3. The persons authorised to carry out the activities referred to in the paragraph. 2 shall be subject to the presentation of an authorisation issued by the supervising authority.
Article 51. [ Warrant for the destruction of poppy or hemp crops] Where the production of poppy or fibre hemp is found in a manner that is not in conformity with Article 46 and 47 of the mayor (mayor, president of the city), issue a warrant for the destruction of these crops by ploughing, digging the land or otherwise, which will ensure the effective execution of this order, at the expense of the cultivator; the order shall be given immediate rigor feasibility.
Article 52. [ Commissioned municipalities in the field of government administration] The tasks referred to in Article 47, 50 and 51, are carried out by the municipality as tasks commissioned from the scope of government administration.
Chapter 6a
Penalty payment
Art. 52a. [ Financial penalty for the manufacture or placing on the market of surrogate measures] 1. Who produces or markets in the territory of the Republic of Poland a substitute or a new psychoactive substance, is subject to a monetary penalty in the amount of between 20 000 PLN and 1 000 000 PLN.
2. The monetary penalty referred to in paragraph 1 shall be provided for in paragraph 2. 1, by decision, by decision, by the State Sanitary Inspector, due to the place of manufacture or placing on the market of a replacement or new psychoactive substance. This decision shall be given immediate enforceability.
3. Establishing the amount of the monetary penalty referred to in paragraph. 1, the State Sanitary Inspector shall take into account in particular the quantity of replacement or manufactured or placed on the market of a new psychoactive substance, manufactured or marketed.
Chapter 7
Penal provisions
Article 53. [ Prohibition of the manufacture of narcotic drugs or psychotropic substances] 1. Who, contrary to the provisions of the Act, produces, processes or terminates narcotic drugs or psychotropic substances or processes poppy straw,
shall be punished by imprisonment for the years 3.
2. If the object of the act referred to in paragraph 1 1, there is a significant amount of narcotic drugs, psychotropic substances or manic straw or the act has been committed to achieve a property or personal gain, the perpetrator
shall be punished by the fine and punishable by imprisonment for a period of not less than 3 years.
Article 54. [ Prohibition of having instruments for the manufacture of narcotic drugs or psychotropic substances] 1. He who express, possesses, stores, disposal or acquires instruments, if the circumstances show that they serve or are intended for unauthorised manufacture, processing or processing of narcotic drugs or psychotropic substances,
shall be punished by the fine, punishable by restriction of liberty or imprisonment by the year 2.
2. The same penalty shall be subject to who:
1) adapt to the unauthorised manufacture, processing, processing or consumption of narcotic drugs or psychotropic substances vessels and instruments, even if they have been produced for a different purpose, or
2) enter into an agreement with another person in order to commit the offence referred to in art. 53 (1) 2.
Article 55. [ Import, export of prohibited measures contrary to the provisions of the Act] 1. Who, contrary to the provisions of the Act, makes the import, export, transport, intra-Community acquisition or intra-Community supply of narcotic drugs, psychotropic substances or poppy straw,
shall be punished by the fine and punishable by the 5 years.
2. In a case of lesser weight, the culprit
shall be punished by the fine, punishable by restriction of liberty or imprisonment by the year
3. If the object of the act referred to in paragraph 1 1, there is a significant amount of narcotic drugs, psychotropic substances or manic straw or the act has been committed to achieve a property or personal gain, the perpetrator
shall be punished by the fine and punishable by imprisonment for a period of not less than 3 years.
Article 56. [ Non-authorised marketing of narcotic drugs, psychotropic substances or poppy straw] 1. Who, contrary to the provisions of art. 33-35, art. 37 and art. 40, the drugs, psychotropic substances or manic straw are either placed on the market or have been marketed,
shall be punished by the fine and punishable by deprivation of liberty from the 6 months to 8 years.
2. In a case of lesser weight, the culprit
shall be punished by the fine, punishable by restriction of liberty or imprisonment by the year
3. If the object of the act referred to in paragraph 1 1, there is a significant amount [ 11] narcotic drugs, psychotropic substances or poppy straw, perpetrator
shall be punished by the fine and punishable by deprivation of liberty from 2 to 12 years.
Article 57. [ Punishment for preparing for a crime] 1. Who makes the preparation for the offence referred to in art. 55 par. 1 or Art. 56 par. 1,
shall be punished by the fine, punishable by restriction of liberty or imprisonment by the year 2.
2. Who makes the preparation for the offence referred to in art. 55 par. 3 or Article 56 par. 3,
shall be punished by imprisonment for the years 3.
Article 58. [ The provision of a narcotic or psychotropic substance to minors] 1. Who, contrary to the provisions of the Act, gives a different person to a narcotic or psychotropic substance, facilitates or makes it possible to use or urge them to use such a means or substances,
shall be punished by imprisonment for the years 3.
2. If the perpetrator of the act referred to in paragraph 1, provide a narcotic or psychotropic substance to a minor or urge him to use such a means or substance, or to give them in significant quantities to another person,
shall be punished by deprivation of liberty from 6 months to the age of 8.
Article 59. [ Unpermitted trade in narcotic drugs or psychotropic substances] 1. Who, in order to achieve a property or personal gain, grants to another person a narcotic or psychotropic substance, facilitates the use or solicitation for the use of such a means or substances,
shall be punished by imprisonment from the year to the years 10.
2. If the perpetrator of the act referred to in paragraph 1, provides a narcotic or psychotropic substance to a minor, facilitates the use or solidifies it for the use of such a substance or substance,
shall be punished by imprisonment for a time not less than the age of 3.
3. In a case of lesser weight, the culprit
shall be punished by the fine, punishable by restriction of liberty or imprisonment by the year 2.
Article 60. [ Non-notification of criminal law enforcement authorities] Who, being the owner or acting on his behalf, the manager or manager of the catering establishment, the entertainment facility or other service activities, having a reliable message about the commission of the offence referred to in art. 56, 58 or 59 on the premises of the establishment or premises shall not immediately inform the law enforcement authorities,
shall be punished by the fine, punishable by restriction of liberty or imprisonment by the year 2.
Article 61. [ Illegal storage and rotation of precursors] Who, contrary to the provisions of the Act, Regulation 273/2004 or Regulation 111/2005, for the purpose of unauthorised manufacture of narcotic drugs or psychotropic substances, produces, processes, terminates, imports, exports, intra-Community the acquisition, intra-Community supply, carried over the territory of the Republic of Poland or the territory of another State, acquires, possesses, stores or markets precursors,
shall be punished by the fine and punishable by the 5 years.
Article 62. [ Not permitted to have narcotic drugs or psychotropic substances] 1. [ 12] Who, contrary to the provisions of the Act, has narcotic drugs or psychotropic substances,
shall be punished by imprisonment for the years 3.
2. If the object of the act referred to in paragraph 1 1, there is a significant amount [ 13] narcotic drugs or psychotropic substances, perpetrator
shall be punished by imprisonment from the year to the years 10.
3. In a case of lesser weight, the culprit
shall be punished by the fine, punishable by restriction of liberty or imprisonment by the year
Article 62a. [ Closure of proceedings] If the object of the act referred to in Article 62 ust. 1 or 3, are narcotic drugs or psychotropic substances in a number of insignificant, for their own use of the offender, proceedings may also be remitted before the decision to open an investigation or investigation, if the judgment against the perpetrator The penalty would be non-elated due to the circumstances of committing the act, and the degree of its social harm.
Article 63. [ Illegal poppy cultivation] 1. [ 14] Who, contrary to the provisions of the Act, cultivates poppy seeds, with the exception of the uncomposed poppy, hemp, with the exception of hemp hemp, or shrub shrubs,
shall be punished by imprisonment for the years 3.
2. The same penalty is subject to who, contrary to the provisions of the Act, collects lactic-malic, opium, poppy straw, leaves of blankets, resin or herbs of hemp other than non-fibrous.
3. If the object of the act referred to in paragraph 1 1, is the cultivator capable of delivering a significant amount of poppy straw, coca leaf, resin or hemp of hemp other than non-wovens, the perpetrator
shall be punished by deprivation of liberty from 6 months to the age of 8.
Article 64. [ Restoration of narcotic drugs, psychotropic substances, malic lactate or poppy straw] 1. Who takes, for appropriation, narcotic drugs, psychotropic substances, manic lactate or poppy straw,
shall be punished by imprisonment from 3 months to the age of 5.
2. If the object of the act referred to in paragraph 1 1, there is a significant amount of narcotic drugs, psychotropic substances, malic lactate or poppy straw, perpetrator
shall be punished by imprisonment from the year to the years 10.
3. The same punishment is subject to, who is stealing from the burglary of narcotic drugs, psychotropic substances, manic lactate or poppy straw.
4. In a case of lesser weight, the culprit
shall be punished by the fine, punishable by restriction of liberty or by imprisonment by the year.
Article 65. [ The law of the uncomposed poppy or hemp cannabis against the provisions of the Act] Who, contrary to the provisions of the Act, cultivates poppy seed or nonwovens,
shall be punishable by
Article 66. [ Unpermitted Precursor Rotation] Who, contrary to the provisions of the Law, Regulation (EC) No 273/2004 or Regulation (EC) No 111/2005, manufacters, processes, terminates, applies, imports, exports, intra-Community acquisitions, intra-Community supplies, carried over the territory of the Republic of Poland. The Polish or the territory of another State, acquires, owns or stores precursors,
shall be punishable by
Article 67. [ Failure to comply with regulatory obligations] Who, contrary to the provisions of the Law, Regulation 273/2004 or Regulation 111/2005, does not comply with the obligation to keep records of the manufacture, processing, processing of narcotic drugs, psychotropic substances or precursors, or other trade in other the way in which the rules on the application of the measures, substances or precursors and the marketing of the substances,
shall be punishable by
Article 68. [ Illegal advertisement] Who runs an advertisement or promotion contrary to the prohibitions set out in art. 20 para. 1 or 3, is subject to a fine, punishable by restriction of liberty or imprisonment by the year.
Article 69. [ Application of provisions of the Code of Conduct on Offense Cases] 1. Orzecking in cases of acts specified in art. 65-67 shall be subject to the provisions on conduct in the case of a misdemeus.
2. In the event of punishment for the offence referred to in Art. 65 or 66 shall be forfeited by the forfeiture of items of offence and of items directly or indirectly derived from the offence, even if they have not been the property of the perpetrator. The court, ruling the forfeiture of objects, may order their destruction. The protocol shall be drawn up for destruction.
Article 70. [ The forfeiture of the subject matter] 1. [ 15] In the event of convictions for offences referred to in art. 53-61, 63 and 64 may be found to be forfeited by the object of the offence and the objects and tools which served or were intended to be committed, even if they were not owned by the perpetrator.
2. In the event of a conviction for the offence referred to in art. 62 and in the case of redemption or conditional remission of criminal proceedings, the forfeiture of a narcotic agent or psychotropic substance shall be adjudicated, even if it was not owned by the perpetrator. The court, ruling the forfeiture of objects, may order their destruction. The protocol shall be drawn up for destruction.
3. The seizure shall not rule if the narcotic or psychotropic substance is the property of a third party and the perpetrator has obtained them by means of a criminal offence or has entered into their possession in a manner grossly violating the obligations of the workers or the terms of the contract linking it with the owner of these narcotic drugs or psychotropic substances.
4. In the event of a conviction for the offence referred to in art. 53-63 The court may rule on the purpose of preventing and combating drug addiction in the amount of up to 50 000 PLN.
5. The provision of the paragraph. 4 shall not apply to the perpetrator of the offence referred to in Article 4. 62 ust. 1 if he is an addicted person.
Art. 70a. [ Collection of information on use by the accused of intoxicants] 1. If there is a reasonable suspicion that the perpetrator is a person addicted or using the harmful psychoactive substance, the court, and in the preparatory proceedings of the procurator, shall manage the meeting by persons who, under the principles indicated in the law obtained a certificate of addiction therapy specialist, information on the use by the accused of narcotic drugs, psychotropic substances or surrogate agents.
2. The Minister of Justice, in agreement with the Minister of Health, shall determine, by means of a regulation, the detailed conditions and the mode of collection of the information referred to in paragraph 1. 1, the conditions to be fulfilled by the persons entitled to carry out those tasks and the amount of the lump sum for the collection of the information, with a view to bringing together the relevant data on the accused person from the point of view of the possibilities and the purpose of the adviser the application of the measures provided for in Article 71 and 72.
Article 71. [ Suspension of the custodial sentence] 1. In the event of the conviction of a person subject to a criminal offence in connection with the use of a narcotic or psychotropic substance on a custodial sentence, the execution of which is conditionally suspended, the court obliges the sentenced person to surrender treatment or rehabilitation in the medicinal product within the meaning of the medical regulations and shall be given to the designated person, institution or association under the supervision of a designated person, institution or association.
2. The Tribunal may order the execution of a suspended custodial sentence if the convicted in the trial period is waived by the obligation referred to in the paragraph. 1, or a flagrant violation of the rules of the plant to which it is addressed is permitted.
3. In the event of the conviction of an addict person, subject to the conditions set out in the paragraph. 1, for a custodial sentence without the conditional suspension of its execution, the court may rule the placement of the perpetrator before the execution of the sentence in the appropriate medicated entity.
4. The time of stay in the medical entity shall not be determined in advance, however, it shall not be longer than 2 years. On the basis of the results of treatment or rehabilitation, the court shall decide on the release of the medicinal product. If the convicted person is not treated or rehabilitated, or a gross violation of the rules of procedure is permitted, the exemption may also be granted at the request of the medicinal product.
5. The court resolves after the termination of treatment or rehabilitation, whether the case-sentence of imprisonment should be executed.
6. The Minister for Health in consultation with the Minister of Justice shall determine, by means of a regulation, the detailed conditions and the procedure for the treatment or rehabilitation of the addicts referred to in paragraph. 1-3, with a view to the well-being of the dependent person.
Article 72. [ Suspension of proceedings by the prosecutor] 1. If a person who is dependent on or uses the harmful psychoactive substance which has been alleged to have committed a criminal offence in connection with the use of a narcotic or psychotropic substance at risk of deprivation of liberty for a maximum of 5 years, treatment, rehabilitation or participation in an educational and prophylactic programme conducted by a medicinal product or other health care provider, the prosecutor may stay the proceedings until the end of the treatment, rehabilitation or participation in the program.
2. After taking the proceedings, the procurator, having regard to the results of the treatment, rehabilitation or participation in the educational and prophylactic program, decides to continue the proceedings or occurs to the court with a request for conditional remission of proceedings.
3. In order to continue the proceedings, the suspected person shall be entitled to a complaint.
4. In the case referred to in paragraph. 2, the conditional remission of proceedings may also be applied to the perpetrator of a criminal offence not exceeding 5 years of imprisonment. The application of the conditional redemption of the proceedings does not prevent the perpetrator's prior criminal prosecution.
Article 73. [ Suspension of legal proceedings] Article Recipe 72 shall apply mutatis mutandis in court proceedings until the closure of the judicial cable.
Article 73a. [ Break in execution of the sentence] 1. If they speak for this medicinal and educational considerations, to a convicted reliant on narcotic drugs or psychotropic substances serving a custodial sentence for a criminal offence committed in connection with the use of narcotic drugs or psychotropic substances may be interrupted in the execution of the custodial sentence referred to in Article 4. 153 § 1 of the Criminal Code of the Executive, in order to undertake treatment or rehabilitation.
2. The condition of the interruption shall be demonstrated by the convicted that he is guaranteed a place of treatment or rehabilitation in the appropriate medical entity corresponding to his therapeutic needs.
3. A penitentiary court refuses to give a break in the execution of a custodial sentence for a crime committed in connection with the use of narcotic drugs or psychotropic substances, if the convicted did not consent to the subject of the sentence, treatment or rehabilitation referred to in art. 117 of the Criminal Code.
4. The sharing of a break in the execution of a custodial sentence shall be admissible if the sentenced to the end of serving a custodial sentence is left no more than 2 years.
5. In the case referred to in paragraph. 1, the penitentiary court, after the termination of treatment or rehabilitation and taking into account their results, manages the further execution of the custodial sentence or conditionally release the convicted from serving the rest of the prison sentence, regardless of whether they are the conditions referred to in Article 4 are met. 78 Penal Code.
Article 74. [ Exemptions from the application of the provisions of the Criminal Code] The provisions of this Chapter shall not apply to the provisions of this Chapter. 96-98 of the Penal Code.
Chapter 8
Amendments to the provisions in force and transitional and final provisions
Article 75. (bypassed).
Article 76. (bypassed).
Article 77. (bypassed).
Article 78. (bypassed).
Article 79. (bypassed).
Article 80. (bypassed).
Article 81. (bypassed).
Article 82. [ Validity of permits] Authorisations issued on the basis of art. 23 (1) 1-3 and 8, art. 25 par. 2 and 3 and Article 3 27 ust. 1 and 2 of the Act referred to in art. 90, shall remain valid after the entry into force of this Act.
Article 83. [ Permit for substitutional treatment] Authorisations for substitutable treatment issued on the basis of existing provisions shall become effective as from the date of entry into force of the Act of Authorisation referred to in Article 28.
Article 84. [ The validity of the permit for the cultivation of poppy or fibrous hemp] 1. Licences for the cultivation of poppy or hemp fibre issued before the date of entry into force of this Act expire on 31 December 2005.
2. Where the holder of the authorisation referred to in paragraph 2 is subject to the authorisation referred to in paragraph 1 1, request, by 31 December 2005, with an application for authorization to carry out activities in the scope of the buying-in of maku or hemp, the existing authorisation shall remain valid until the date on which the decision is taken after the examination the proposal will become final.
Article 85. [ Certificates] Certificates of completion of specialist training in the field of drug addiction in the field of addiction therapy specialist and an addiction therapy instructor obtained before the entry into force of this law become certificates an addiction therapy specialist and an addiction therapy instructor within the meaning of the provisions of this Act.
Article 86. [ Obligation to complete training] Persons employed on the day of entry into force of this Act in rehabilitation units who did not obtain a certificate of addiction therapy specialist or an addiction therapy instructor are obliged to complete the training referred to in art. 27 ust. 1, within a period of 5 years from the date of entry into force of the Act.
Article 87. (bypassed).
Article 88. [ National Bureau of Action Against Drug Addiction After the Introduction of the Act] 1. The National Bureau of Action Against Drug Addiction, acting under this Act, shall enter into all the rights and obligations of the National Bureau for the Addiction of Narkomania, acting on the basis of art. 3a (3) 1 of the Act referred to in art. 90.
2. Mies used by the National Anti-Addiction Office acting on the basis of art. 3a (3) 1 of the Act referred to in art. 90, becomes on the date of entry into force of the Act on the ground used by the National Bureau for the Action Against Drug Addiction operating under this Act.
3. The transition of the rights and property of the National Bureau for the Addiction of Narkomania acting on the basis of art. 3a (3) 1 of the Act referred to in art. 90, the National Bureau of Action Against Drug Addiction, acting on the basis of this Law, shall be free of charge and shall be free of taxes and charges.
4. Workers of the National Bureau for the Addiction of Narkomania acting on the basis of art. 3a (3) 1 of the Act referred to in art. 90, on the date of entry into force of the Act, become employees of the National Bureau for the Action Against Drug Addiction operating under this Act.
Article 89. [ Provisions so far] Implementing acts issued on the basis of Article 5 par. 6, art. 9 ust. 4, art. 11 (1) 3, art. 12 (1) 3, art. 14 para. 4, art. 15 para. 5, art. 16, art. 22 par. 5, art. 23 (1) 14, art. 24 ust. 2, art. 25 par. 4, art. 27 ust. 6, art. 28 para. 4, art. 29 par. 2, art. 30 par. 2, art. 31 par. 2b and art. 56 par. 6 of the Act referred to in art. 90 of this Act shall retain the power until the date of entry into force of the provisions issued on the basis of art. 7 ust. 5, art. 12 (1) 4, art. 22 par. 3, art. 23 (1) 4, art. 24 ust. 6, art. 27 ust. 12 and 13, art. 28 para. 7, art. 29 par. 2, art. 34 par. 5, art. 35 par. 10, art. 36 ust. 3, art. 37 par. 12, art. 38 par. 5, art. 40 par. 6, art. 41 par. 5, art. 42 par. 2, art. 43 par. 2 and Art. 44 par. 9.
Article 90. [ Repealed provisions] The Law of 24 April 1997 is repealed. anti-drug addiction (Dz. U. 2003 r. No 24, pos. 198 i No 122, pos. 1143, 2004 No. 238, pos. 2390 and 2005 Nr 175, pos. 1462).
Article 91. [ Entry into force] The Act shall enter into force after 14 days from the day of the announcement.
Annex 1. [ LIST OF INTOXICANTS]
Annexes to the Act of 29 July 2005.
Annex No 1
LIST OF INTOXICANTS
1. Intoxicating agents of I-N groups
| Seq. |
International recommended names |
Other names |
Chemical determinations |
|
|
1 |
2 |
3 |
| 1. |
|
5-FUR-144 |
[ 1-(5-fluoropentyl) -1 H -indol-3-yl] (2,2,3,3-tetramethylcyclopropyl) methanone |
| 2. |
|
5F-AKB-48 |
N -(1-adamantyl) -1-(5-fluoropentyl) -1 H -indazol-3-carboxamide, ie 1-(5-fluoropentyl)- N -tricyclo[3.3.1.133, 7] decan-1-yl-1 H -indazol-3-carboxamide |
| 3. |
|
5F-PB-22 |
quinolin-8-yl ester of 1-(5-fluoropentyl) -1 H -indol-3-carboxylic |
| 4. |
|
A-834,735 |
1-[ (tetrahydropyran-4-yl) methyl] -1 H -indol-3-yl-(2,2,3,3-tetramethylcyclopropyl) methanone |
| 5. |
|
AB-001 |
(1-adamant-1-yl) (1-pentyl-1 H -indol-3-yl) methanone |
| 6. |
|
AB-FUBINACA |
N-(1-amino-3-methyl-1-ocsobutan-2-yl) -1-(4-fluorobenzyl) -1 H -indazol-3-carboxamide |
| 7. |
ACETORPHINE |
|
3- O -acetyl-6,7,8,14-tetrahydro-7α-(1-hydroxy-1-methylbutyl)-6,14-endo-etenooripavine |
| 8. |
|
Acetyl-α-methylfentanyl |
N -[ 1-(α-methylphenethyl) -4-piperidyl] acetanilide |
| 9. |
ACETYLMETHIDOL |
|
3-acetoxy-6-dimethylamino-4,4-diphenyleheptane |
| 10. |
|
AH-7921 |
3,4-dichloro-N-[ (1-dimethylamino) cyclohexyl-methyl] benzamide |
| 11. |
ALPHAACETYLMETHIDOL |
|
α-3-acetoxy-6-dimethylamino-4,4-diphenylheptane, or (3 R , 6 R ) -3-acetoxy-6-dimethylamino-4,4-diphenylheptane |
| 12. |
ALFAMEPRODINE |
|
α-3-ethyl-4-phenyl-1-methyl-4-propionyloxperidine, i.e. cis-3-ethyl-4-phenyl-1-methyl-4-propionyloxperidine |
| 13. |
ALFAMETADOL |
|
α-6-dimethylamino-4,4-diphenyl-3-heptanol, i.e. (3 R , 6 R ) -6-dimethylamino-4,4-diphenyl-3-heptanol |
| 14. |
|
α-Methylfentanyl |
N-[ 1 -(α-methylphenethyl) -4-piperidyl] propionanilide |
| 15. |
|
α-Methylthiophentanl |
N -{1-[ 1-methyl-2-(2-thienyl) ethyl] -4-piperidyl} propionanilide |
| 16. |
ALPHAPRODINE |
|
Α-4-phenyl-1,3-dimethyl-4-propionyloxperidine, or cis-(+ /-) -4-phenyl-1,3 -dimethyl-4-propionyloyloxperidine |
| 17. |
ALFFENTANYL |
|
N -[ 1-[ 2-(4-ethyl-4,5-dihydro-5-oxo-1 H -tetrazol-1-yl) ethyl] -4-(methoxymethyl) -4-piperidinyl] -N-phenylpropanamide |
| 18. |
ALLILOPRODINE |
|
3-Allyl-4-phenyl-1-methyl-4-propionyloxperidine |
| 19. |
AM-694 |
|
1-[ (5-fluoropentyl) -1 H -indol-3-yl] (2-iodofenyl) methanone |
| 20. |
AM-1220 |
|
1-[ (1-methylpiperidin-2-yl) methyl] -1 H -indol-3-yl-(naphthalen-1-yl) methanone |
| 21. |
|
AM-1248 |
1-{[ ( N -methylpiperidin-2-yl) methyl] -1 H -indol-3-yl} (1-adamantyl) methanone |
| 22. |
AM-2201 |
|
1-[ (5-fluoropentyl) -1 H -indol-3-yl] -1-naphthylmethanone |
| 23. |
|
AM-2233 |
1-{[ ( N -methylpiperidin-2-yl) methyl] -1 H -indol-3-yl} -2-cy-enzylomethanone |
| 24. |
ANILERIDINE |
|
ethyl 1-p-aminophenethyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester |
| 25. |
|
APICA SDB-001, 2NE1 |
N -(1-adamantyl) -1-pentyl-1 H -indol-3-ylcarboxamide |
| 26. |
|
APINACA AKB-48 |
N -(1-adamantyl) -1-pentyl-1 H -indazol-3-ylcarboxamide |
| 27. |
ARGYREIA NERVOSA-live plants or droughts, seeds, extracts, and extracts |
|
|
| 28. |
BANISTERIOPSIS CAAPI-live plants or droughts, seeds, extracts and extracts |
|
|
| 29. |
BENZETYDYNA |
|
ethyl 1-(2-benzyloxyethyl) -4-phenyl-4-piperidinecarboxylic acid ethyl ester |
| 30. |
BENZYLOMORFINA |
|
3-Benzylomorphine, or 3-benzyloxy- 7,8-didehydro-4,5-α-epoxy- 17-Methylmorphine-6α-ol |
| 31. |
BETACETYLMETHADOL |
|
β-3-acetoxy-6-dimethylamino-4,4-diphenylheptane |
| 32. |
|
β-Hydroxyfentanyl |
N -[ 1-(β-hydroxyphenethyl) -4-piperidyl] propionanilide |
| 33. |
|
β-Hydroxy-3-methylfentanyl |
N -[ 1-(β-hydroxyphenethyl) -3-methyl-4-piperidyl]-propionanilide |
| 34. |
BETAMEPRODINE |
|
β-3-ethyl-4-phenyl-1-methyl-4-propionyloxperidine |
| 35. |
BETAMETHADOL |
|
β-6-dimethylamino-4,4-diphenyl-3-heptanol, or (3 S , 6 R ) -6-dimethylamino-4,4-diphenyl-3-heptanol |
| 36. |
BETAPRODINE |
|
β-4-phenyl-1,3-dimethyl-4-propionyloxperidine |
| 37. |
BEZYTRAMID |
|
1-(3-cyano-3,3-difenylpropyl) -4-(2-oxo-3-propionyl-1-benzimidazolinyl) piperidine |
| 38. |
|
Butyrfentanyl |
N -phenyl- N -[ 1-(2-phenylethyl) piperidin-4-yl] butanamide |
| 39. |
|
4-Fluoro-butyrfentanyl |
N -(4-fluorophenyl)- N -[ 1-(2-phenylethyl) piperidin-4-yl] butanamide |
| 40. |
CALEA ZACATECHICHI- |
|
|
| 41. |
CATHA EDULIS- |
|
|
| 42. |
CP 47,497 |
|
5-(1,1-dimethylheptyl) -2-[ (1RS, 3SR) -3-hydroxycyclohexyl]-phenol |
| 43. |
CP 47,497-C6-Homologist |
|
5-(1,1-dimethylhexyl) -2-[ (1RS, 3SR) -3-hydroxycyclohexyl]-phenol |
| 44. |
CP 47,497-C8-Homologist |
|
5-(1,1-dimethyloctyl) -2-[ (1RS, 3SR) -3-hydroxycyclohexyl] -phenol |
| 45. |
CP 47,497-C9-Homologist |
|
5-(1,1-dimethylonyl) -2-[ (1RS, 3SR) -3-hydroxycyclohexyl]-phenol |
| 46. |
DEXTROMORAMIDE |
Palfium |
(+) -4-[ 3,3-diphenyl-2-methyl-4-oxo-4-(1-pyrrolidinyl)-butyl]-morpholine, or (+) -1-(2,2-diphenyl-3-methyl-4-morpholinobutyryl) pyrrolidine |
| 47. |
DEZOMORPHINE |
|
dihydrodeoxymorphine, or 4,5-epoxy-3-hydroxy-17-methylbutyfinate |
| 48. |
DIAMPROMIDE |
|
N -[ 2-N-methyl-( N -phenethylamino)-propyl] propionanilide |
| 49. |
DIETYLOTIAMBUTEN |
|
3-diethylamino-1,1-bis (2 '-thienyl) but-1-ene |
| 50. |
DIFENOXYLATE |
|
ethyl 1-(3-cyano-3,3-difenylpropyl) -4-phenyl-4-piperidinecarboxylic acid ethyl ester |
| 51. |
DIFENOXIN |
|
1-(3-cyano-3,3-difenylpropyl) -4-phenyl-4-piperidinecarboxylic acid |
| 52. |
DIHYDROETORPHINE |
|
7,8-Dihydro-7-α-[ 1-(R)-hydroxy-1-methylbutyl]-6,14-endo-ethnotetrahydrooripawine |
| 53. |
DIHYDROMORPHINE |
|
4,5α-epoxy-17-methylmorphine-3,6α-diol |
| 54. |
DIMEFEPTANOL |
|
6-dimethylamino-4,4-diphenyl-3-heptanol |
| 55. |
DIMENOXADOL |
|
1-ethoxy-1,1-diphenylacetic acid 2-dimethylaminoethyl ester |
| 56. |
DIMETOKAINE |
Larokaine |
3-(diethylamino) -2,2-dimethylpropyl 4-aminobenzoesate |
| 57. |
DIMETHYLTHIAMBUTENE |
|
3-dimethylamino-1,1-bis (2 '-thienyl) but-1-ene |
| 58. |
DIPIPANON |
|
4,4-diphenyl-6-piperidine-3-heptanone |
| 59. |
DROTEBANOL |
|
3,4-dimethoxy-17-methylmorphine-6β, 14-diol |
| 60. |
EAM-2201 |
5-fluoro-JWH-210 4-ethyl-AM-2201 |
4-ethylnaphthalen-1-yl-[ 1-(5-fluoropentyl) indol-3-yl] methanone |
| 61. |
ECHINOPSIS PACHANOI-live plants or droughts, seeds, extracts and extracts |
|
|
| 62. |
EKGONIN |
|
acid [ 1 R -( exo ) ]-3-hydroxy-8-methyl-8-azabicyclo [ 3.2.1] octano-2-carboxylic acid |
| 63. |
ETOXSERYDINE |
|
ethyl 1-[ 2-(2-hydroxyethoxy) ethyl] -4-phenyl-4-piperidynocarboxylic acid ethyl ester |
| 64. |
ETONITAZEN |
|
1-(2-diethylaminoethyl) -2-(p-ethoxybenzyl) -5-nitrobenzimidazole |
| 65. |
ETORFINA |
|
6,7,8,14-tetrahydro-7α-(1-hydroxy-1-methylbutyl) -6,14-enetenooripavine |
| 66. |
ETHYLMETHYLTHIAMBUTENE |
|
3-ethylmethano-1,1-bis (2 '-thienyl) but-1-ene |
| 67. |
FENADOKSON |
|
4,4-diphenyl-6-morpholinoheptan-3-one |
| 68. |
FENAMPROMIDE |
|
N -(1-methyl-2-piperidynoethyl) propionanilide |
| 69. |
PHENAZOCINE |
|
2 '-hydroxy-5,9-dimethyl-2-phenethyl-6,7-benzomorphan, or 3-phenetyl-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methane-3-benzazocyn-8-ol |
| 70. |
FENOMORPHAN |
|
3-hydroxy-17-phenetylomorfinate |
| 71. |
FENOPERIDINE |
|
1-(3-phenyl-3-hydroxypropyl) -4-phenyl-4-piperidinecarboxylic acid ethyl ester |
| 72. |
FENTANYL |
|
1-phenethyl-4-( N -propionylanilino) piperidine, ie N -(1-phenethyl-4-piperidyl) propionanilide |
| 73. |
FLUOROTROPAKOCAINE |
p-FBT p-fluorobenzoyloxytropan |
4-fluorobenzoate-8-methyl-8-azabicyclo [ 3.2.1] oct-3-yl |
| 74. |
FURETYDYNA |
|
ethyl 4-phenyl-1-(2-tetrahydrofurfuryloxyethyl) -4-piperidinecarboxylic acid ethyl ester |
| 75. |
HEROINE |
|
diacetylomorphine, or 3,6α-diacetoxy-7,8-didehydro-4, 5α-epoxy-17-methylbutyfinate |
| 76. |
HU-210 |
|
(6a) R , 10a R ) -9-(hydroxymethyl) -6,6-dimethyl-3-(2-methyloctan-2-yl) -6a, 7,10,10a-tetrahydrobenzo [ c] chromen-1-ol |
| 77. |
HYDROCODONE |
|
dihydrocodeinone, or 4,5α-epoxy-3-methoxy-17-methylmorphine-6-one |
| 78. |
|
3-(4-hydroxymethylbenzoyl) -1-pentylindole |
3-(4-hydroxymethylbenzoyl) -1-pentyloindol |
| 79. |
HYDROXYPETHIDINE |
|
ethyl 4-m-hydroxyphenyl-1-methyl-4-piperidinecarboxylic acid ethyl ester |
| 80. |
HYDROMORFINOL |
|
14-hydroxy-7,8-dihydromorphine |
| 81. |
HYDROMORPHONE |
|
dihydromorphinone, or 4,5α-epoxy-3-hydroxy-17-methylmorphine-6-one |
| 82. |
IZOMETADON |
|
6-dimethylamino-4,4-diphenyl-5-methyl-3-hexanone |
| 83. |
JWH-007 |
2-methyl-1-pentyl-3-(1-naphthoyl) indole |
1-pentyl-2-methyl-3-(1-naphthonyl) indole, or (2-methyl-1-pentyl-1 H -indol-3-yl)-naphthalene-1-ylmethanone |
| 84. |
JWH-015 |
|
(2-Methyl-1-propyl-1 H -indol-3-yl) -1-naphthylmethanone |
| 85. |
JWH-018 |
1-pentyl-3-(1-naphthyl) indole |
Naphthalen-1-yl (1-pentylindol-3-yl) methanone |
| 86. |
JWH-019 |
1-hexyl-3-(1-naphthtoyl) indole |
naphthalen-1-yl (1-hexylindol-3-yl) methanone |
| 87. |
JWH-073 |
1-butyl-3-(1-naphthyl) indole |
naphthalen-1-yl (1-butylindol-3-yl) methanone |
| 88. |
JWH-081 |
|
(4-methoxynaphthalen-1-yl) (1-pentylindol-3-yl) methanone |
| 89. |
JWH-098 |
|
(4-methylnaphthalen-1-yl) (2-methyl-1-pentyl-1 H -indol-3-yl) methanone |
| 90. |
JWH-122 |
1-pentyl-3-(4-methyl-1-naphthyl) indole |
(4-methylnaphthalen-1-yl) (1-pentyl-1 H- indol-3-yl) methanone |
| 91. |
JWH-166 |
|
(6-methoxynaphthalen-1-yl) (1-pentyl-1 H -indol-3-yl) methanone |
| 92. |
JWH-200 |
|
(1-(2-morpholin-4-ylethyl) indol-3-yl) naphthalen-1-ylmethanone |
| 93. |
JWH-201 |
|
2-(4-methoxyphenyl) -1-(1-pentyl-1 H -indol-3-yl) ethanone |
| 94. |
JWH-203 |
2-(2-chloro-phenyl)-1-(1-pentyl-1 H -indol-3-yl)-ethanone |
2-(2-Chlorophenyl) -1-(1-pentylindol-3-yl) ethanone |
| 95. |
JWH-208 |
|
(1-Propyl-1 H -indol-3-yl) (4-propylnaphthalen-1-yl) methanone |
| 96. |
JWH-210 |
|
(4-ethylnaphthalen-1-yl) (1-pentylindol-3-yl) methanone |
| 97. |
JWH-250 |
1-pentyl-3-(2-methoxyphenyacetyl) indole |
2-(2-methoxyphenyl) -1-(1-pentylindol-3-yl) ethanone |
| 98. |
JWH-251 |
|
2-(2-methylphenyl) -1-(1-pentyl-1 H -indol-3-yl) ethanone |
| 99. |
JWH-302 |
|
2-(3-methoxyphenyl) -1-(1-pentyl-1 H -indol-3-yl) ethanone |
| 100. |
JWH-307 |
|
[ 5-(2-fluorophenyl) -1-pentyl-1 H -pyrrole-3-yl] naphthalen-1-ylmethanone |
| 101. |
JWH-368 |
|
[ 5-(3-fluorophenyl) -1-pentyl-1 H -pyrrol-3-yl] -1-naphthalenylmethanone |
| 102. |
JWH-398 |
1-pentyl-3-(4-chloro-1-naphthoyl) indole |
(4-chloronaphthalen-1-yl) (1-pentyl-1 H -indol-3-yl) methanone |
| 103. |
|
Kamfetamine |
N -methyl-3-phenylobicyclo [ 2.2.1] heptane-2-amine |
| 104. |
KAVA KAVA-live plants or droughts, seeds, lifts and extracts |
|
|
| 105. |
KETOBEMIDONE |
Cliradon |
4-( m -hydroxyphenyl) -1-methyl-4-propionylpiperidine, or 1-[ 4-(3-hydroxyphenyl) -1-methyl-4-piperidyl] propan-1-one |
| 106. |
CLONITAZEN |
|
2-( p -chlorobenzyl) -1-(2-diethylaminoethyl) -5-nitrobenzimidazole |
| 107. |
CODEOXIM |
|
O -(carboxymethyl) oxym dihydrocodeinone |
| 108. |
Koka LIST |
|
|
| 109. |
KOKAINE |
|
methyl ester of benzoylate, i.e. acid-methyl ester [ 1R -( exo, exo )] ]-3-benzoyloxy-8-methyl-8-azabicyclo [ 3.2.1] octano-2-carboxylic acid |
| 110. |
NON-wovens and extracts, pharmaceutical products and all other extracts of hemp other than non-wovens |
|
|
| 111. |
LEONOTIS LEONURUS-live plants or droughts, seeds, extracts, and extracts |
|
|
| 112. |
LEWOMETORFAN |
|
(-) -3-methoxy-17-methylmorphine |
| 113. |
LEWOMORAMID |
|
(-) -4-[ 2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl) butyl] morpholine, or (-) -1-(2,2-diphenyl-3-methyl-4-morpholinobutyryl) pyrrolidine |
| 114. |
LEWORFANOL |
|
(-) -3-hydroxy-17-methylmorphine |
| 115. |
LEWOTENACYLOMORFAN |
|
(-) -3-hydroxy-17-phenacylomorfinate |
| 116. |
POPPY STRAW CONCENTRATES-products arising in the process of obtaining alkaloids from poppy straw, if these products are placed on the market |
|
|
| 117. |
POPPY STRAW EXTRACTS-other than concentrates of products obtained from poppy straw with water extraction or any other solvent, as well as other products obtained by the processing of malic lactate |
|
|
| 118. |
|
MAM-2201 |
[ 1-(5-fluoropentyl) -1 H -indol-3-yl] (4-methyl-1-naphthyl) methanone |
| 119. |
METADON |
|
6-dimethylamino-4,4-diphenyl-3-heptanone |
| 120. |
METHADONE SEMI-PRODUCT |
|
4-cyano-2-dimethylamino-4,4-diphenylbutane |
| 121. |
METAZOCYNA |
|
2 '-hydroxy-2,5,9-trimethyl-6,7-benzomorfan |
| 122. |
METTYRES |
|
5-methyldihydromorphinone, or 4,5-epoxy-3-hydroxy-5,17-dimethylmorphinoan-6-one |
| 123. |
METHYLREZORPHINE |
|
6-Methyl- 6 -deoxymorphine |
| 124. |
METHYLDIHYDROMORPHINE |
|
6-Methyldihydromorphine |
| 125. |
|
3-Methylfentanyl |
N -(1-phenethyl-3-methyl-4-piperidyl) propionanilide (form cis -and form trans -) |
| 126. |
|
3-Methylthiophentanil |
N -[ 3-methyl-1-[ 2-(2-thienyl) ethyl] -4-piperidyl] propionanilide |
| 127. |
MIMOSA TENUIFLORA-live plants or droughts, seeds, extracts and extracts |
MIMOSA HOSTILIS |
|
| 128. |
MIROFINA |
|
myriystylbenzylomorphine, or 3-benzyloxy-7,8-didehydro-4, 5α-epox-6α-mirystoiloxy-17-methylmorphine of tetradecanoate |
| 129. |
MITRAGYNA SPECIOSA-live plants or droughts, seeds, extracts, and extracts |
|
|
| 130. |
MITRAGYNINE |
|
Acid-methyl ester (E) -2-[ ( 2S , 3S ) -3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo [ 3,2-h] quinoliin-2-yl] -3-methoxyprop-2-enoic |
| 131. |
MORAMIDE SEMI-PRODUCT |
|
1,1-diphenyl-2-methyl-3-morpholinomasal acid |
| 132. |
MORFERYDYNA |
|
ethyl 4-phenyl-1-(2-morpholinoethyl) -4-piperidinecarboxylic acid ethyl ester |
| 133. |
MORFINA |
|
7,8-didehydro-4, 5α-epoxy-17-methylmorphine-3,6α-diol |
| 134. |
MORPHINE OF METHYLBROMIDE and other morfins containing quaternary nitrogen |
|
|
| 135. |
MORPHINE N-OXIDE |
|
N -7,8-didehydro-4, 5α-epoxy-17-methylmorphine-3,6α-diol oxide |
| 136. |
|
MPPP |
4-Phenyl-1-methyl-4-piperidinol propionate |
| 137. |
|
MT-45 |
(1-cyclohexyl-4-(1,2-diphenylethyl) piperazine) |
| 138. |
NALBUPHINE |
|
3-(cyclobutylmethyl) -1,2,4,5,6,7,7-α, 13-octahydro-4,12-metanobenzofuro [ 3,2-e] isoquinolino-4-α, 7,9-triol |
| 139. |
NIKOMORFINA |
|
3,6-dinicottynoilomorphine |
| 140. |
NORACYMETADOL |
|
α-(+) -3-acetoxy-4,4-diphenyl-6-methylaminoheptane |
| 141. |
NORLEWORFANOL |
|
(-) -3-hydroxymorphinate |
| 142. |
NORMETADON |
|
6-dimethylamino-4,4-diphenyl-3-hexanone |
| 143. |
NORMORFINA |
|
demethylomorphine, or 7,8-didehydro-4, 5α-epoksymorfinan-3,6α-diol |
| 144. |
NORPIPANON |
|
4,4-diphenyl-6-piperidine-3-hexanone |
| 145. |
NYMPHAEA CAERULEA-live plants or droughts, seeds, lifts and extracts |
|
|
| 146. |
OPIUM AND OPIUM TINCTURE |
|
|
| 147. |
OXYCODONE |
Eucodal |
14-hydroxy-dihydrocodeeinone, or 4,5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one |
| 148. |
PERSIMORFON |
|
14-hydroxdihydromorphinone, or 4,5α-epoxy-3,14-dihydroxy-17-methylmorphine-6-one |
| 149. |
PEGANUM HARMALA-live plants or droughts, seeds, extracts and extracts |
|
|
| 150. |
|
Para-fluorofentanyl |
4 '-fluoro- N -(1-phenethyl-4-piperidyl) propionanilide |
| 151. |
|
PEPAP |
1-phenethyl-4-phenyl-4-piperidinol acetate |
| 152. |
PETIDINE |
Dolargan |
ethyl 4-phenyl-1-methyl-4-piperidinecarboxylic acid ethyl ester |
| 153. |
PETHIDINE SEMI-PRODUCT A |
|
4-cyano-4-phenyl-1-methylpiperidine |
| 154. |
PETHIDINE SEMI-PRODUCT B |
|
ethyl 4-phenyl-4-piperidinecarboxylic acid ethyl ester |
| 155. |
PETHIDINE SEMI-PRODUCT C |
|
4-Phenyl-1-methyl-4-piperidinecarboxylic acid |
| 156. |
PIMINODINE |
|
ethyl 4-phenyl-1-(3-phenylaminopropyl) -4-piperidinecarboxylic acid ethyl ester |
| 157. |
PYRITRAMIDE |
|
1-(3-cyano-3,3-diphenylpropyl) -4-(1-piperidino) -4-piperidinecarboxylic acid, that is, 1 '-(3-cyano-3,3-diphenylpropyl)-(1,4'-bipiperidino) -4 '-carboxylic acid |
| 158. |
PROHEPTAZINE |
|
4-phenyl-1,3-dimethyl-4-propionyloxycyclazacycloheptane |
| 159. |
PROPERYDYNA |
|
isopropyl ester of 4-phenyl-1-methyl-4-piperidynocarboxylic acid |
| 160. |
PSYCHOTRIA VIRIDIS-live plants or droughts, seeds, lifts and extracts |
Chacruna |
|
| 161. |
|
QUCHIC BB-22 |
quinolin-8-yl ester of 1-(cyclohexylmethyl) -1 H -indol-3-carboxylic |
| 162. |
|
QUPIC PB-22 |
Quinolin-8-yl ester of 1-pentyl-1 H -indol-3-carboxylic |
| 163. |
RACEMETORFAN |
|
(+ /-) -3-methoxy-17-methylmorphine |
| 164. |
RACEMORAMIDE |
|
(+ /-) -4-[ 3,3 -difenyl-2-methyl-4-oxo-4-(1-pyrrolidinyl) butyl] morpholine |
| 165. |
RACEMORFAN |
|
(+ /-) -3-hydroxy-17-methylmorphine |
| 166. |
|
RCS-2 oRCS-4, orto-isomer RCS-4 |
(2-methoxyphenyl) (1-pentyl-1 H -indol-3-yl) methanone |
| 167. |
RCS-4 |
BTM-4 SR-19 ERIC-4 |
(4-methoxyphenyl) (1-pentyl-1 H -indol-3-yl) methanone |
| 168. |
REMIFENTANYL |
|
1-(2-methoxycarbonylethyl) -4-(phenylpropionylamino)-piperidine-4-carboxylic acid methyl ester |
| 169. |
RIVEA CORYMBOSA-live plants or droughts, seeds, extracts and extracts |
|
|
| 170. |
SALVIA DIVINORUM-live plants or droughts, seeds, lifts and extracts |
|
|
| 171. |
|
STS-135 |
N -(1-adamantyl) -1-(5-fluoropentyl) -1 H -indol-3-carboxamide |
| 172. |
SUFENTANIL |
|
N -[ 4-(methoxymethyl) -1-[ 2-(2-thienyl) ethyl] -4-piperidyl] propionanilide |
| 173. |
|
Synthequin |
L-(thiophen-2-yl) -2-methylaminopropane |
| 174. |
TABERNANTHE IBOGA-live plants or droughts, seeds, lifts and extracts |
|
|
| 175. |
TEBAINE |
|
6,7,8,14-tetradehydro-4, 5α-epoxy-3,6-dimethoxy-17-methylbutyfinate |
| 176. |
TEBAKON |
|
Acetyldihydrocodeinone, or 6-acetoxy-6,7-didehydro-4, 5α-epoxy-3-methoxy-17-methylbutyfinate |
| 177. |
|
Tiofentanil |
N -{1-[ 2-(2-thienyl) ethyl] -4-piperidyl} propionanilide |
| 178. |
|
THJ-018 |
1-naphthalenyl (1-pentyl-1 H -indazol-3-yl) methanol |
| 179. |
TRICHOCEREUS PERUVIANUS-live plants or droughts, seeds, extracts, and extracts |
|
|
| 180. |
TRIMEPERIDINE |
|
4-phenyl-1,2,5-trimethyl-4-propionyloxperidine |
| 181. |
TILIDINE |
|
Ethyl ester of (+)-trans-2-(dimethylamino) -1-phenyl-3-cyclohexen-1-carboxylic acid |
| 182. |
UR-144 |
|
(1-pentyl-1 H -indol-3-yl) (2,2,3,3-tetramethylcyclopropylyl) methanone |
| 183. |
HEMP RESIN |
|
|
| and: -the isomers of the intoxicating agents listed in this group, if such isomers are possible under the chemical designation used, unless such isomers are clearly excluded, -the esters and ethers of the intoxicants listed in this group, if such esters and ethers are possible, unless they are listed in another group, -the salts of the intoxicants listed in this group, including the salts of esters, ethers and isomers referred to above, if such salts are possible. |
|||
2. The intoxicating agents of the group II-N
| International recommended names |
Other names |
Chemical determinations |
| 1 |
2 |
3 |
| ACETYLDIHYDROCODEINE |
|
6-acethyl-7,8-dihydrocodeine |
| CODEINE |
|
3- O -Methylmorphine, or 7,8-didehydro-4,5 α -epoxy-3-methoxy-17-methylmorphine-6 α -ol |
| DEXSTROPROPOXYPHENE |
|
(+) -1,2-diphenyl-4-dimethylamino-3-methyl-2-propionyloxybutane, or propionate (2 S , 3 R )-(+) -1,2-diphenyl-4-dimethylamino-3-methyl-2-butanol |
| DIHYDROCODEINE |
|
7,8-dihydrocodeine |
| ETHYLMORPHINE |
Dionine |
3- O -ethylomorphine |
| FOLKODYNA |
|
morpholethylethylmorphine, which is 7,8-didehydro-4,5 α -epoxy-17-methyl-3-(2-morpholinoethoxy) morphine-6 α -ol |
| NIKODYKODYNA |
|
6-nicotinoyl-7,8-dihydrocodeine |
| NIKOKODYNA |
|
6-nicotinylcodeine |
| NORKODEINE |
|
N -demethylcodeine |
| PROPIRAM |
|
N -(1-methyl-2-piperidynoethyl)- N -(2-pyridyl) propionamide |
| and: -the isomers of the intoxicants listed in this group, if the existence of such isomers is possible under the chemical designation used, unless such isomers are clearly excluded, -the salts of the intoxicants listed in this group, including the salts of esters, ethers and isomers referred to above, if such salts are possible |
||
3. Intoxicating agents of III-N group
1. Preparations containing, in addition to the other constituents of the codeine, the quantity of which does not exceed 50 mg per dose, or the concentration shall not exceed 1,5% in the preparations in undivided form.
2. Preparations containing in addition to other components:
-ACETYLDIHYDROCODEINE
-DIHYDROCODEINE
-ETYLOMORFINA
-NORKODEINA
-NIKODYCODEINE
-NICOXODINE
in which the amount of the intoxicating agent does not exceed 100 mg per dose or the concentration does not exceed 2,5% in the preparations in the undivided form.
3. Preparations containing at most 2,5 mg diphenoxin, calculated as a rule, and not less than 0,025 mg of atropine sulphate in one dose.
4. Preparations containing at one dose not more than 0,5 mg of diphenoxin and such amounts of atropine tartrate, which correspond to at least 5% of the dose of diphenoxin.
4. The IV-N group intoxicants
| International recommended names |
Other names |
Chemical determinations |
| 1 |
2 |
3 |
| ACETORPHINE *) |
|
3- O -acethyl-6,7,8, 14-tetrahydro-7 α -(1-hydroxy-1-methylbutyl) -6,14- endo -etenooripavine |
|
|
Acetylo- α -methylfentanyl |
N-[ 1-( α -methylphenethyl) -4-piperidyl] acetanilide |
|
|
α -Methylfentanyl |
N-[ 1-( α -methylphenethyl) -4-piperidyl] propionanilide |
|
|
3-Methylthiophentanil |
N-[ 3-methyl-1-[ 2-(2-thienyl) ethyl] -4-piperidyl] propionanilide |
|
|
β -Hydroxyfentanyl |
N-[ 1-( β -hydroxyphenethyl) -4-piperidyl] propionanilide |
|
|
β -Hydroxy-3-methylfentanyl |
N-[ 1-( β -hydroxyphenethyl) -3-methyl-4-piperidyl]-propionanilide |
| DEZOMORPHINE |
|
dihydrodeoxymorphine, or 4,5-epoxy-3-hydroxy-17-methylbutyfinate |
| ETORFINA *) |
|
6,7,8,14-tetrahydro-7 α -(1-hydroxy-1-methylbutyl) -6,14- endo -etenooripavine |
| HEROINE |
|
diacetylomorphine, or 3,6 α -diacetoxy-7,8-didehydro-4,5 α -epoxy-17-methylmorphine |
| KETOBEMIDONE |
Cliradon |
4- m -Hydroxyphenyl-1-methyl-4-propionylpiperidine |
| 1 |
2 |
3 |
| Hemp, other than non-wovens |
|
|
|
|
3-Methylfentanyl |
N -(1-phenethyl-3-methyl-4-piperidyl) propionanilide (form of cis-and trans-form) |
|
|
MPPP |
4-Phenyl-1-methyl-4-piperidinol propionate |
|
|
Para-fluorofentanyl |
4 '-fluoro- N -(1-phenethyl-4-piperidyl) propionanilide |
|
|
PEPAP |
1-phenethyl-4-phenyl-4-piperidinol acetate |
|
|
Tiofentanil |
N -[ 1-[ 2-(2-thienyl) ethyl] -4-piperidyl] propionanilide |
| HEMP RESIN |
|
|
| and: -the isomers of the intoxicating agents listed in this group, if such isomers are possible under the chemical designation used, unless such isomers are clearly excluded, -the esters and ethers of the intoxicants listed in this group, if such esters and ethers are possible, unless they are listed in another group, -the salts of the intoxicants listed in this group, including the salts of esters, ethers and isomers referred to above, if such salts are possible |
||
| *) It can be used in animal treatment. |
||
Annex 2. [ LIST OF PSYCHOTROPIC SUBSTANCES]
Annex No 2
LIST OF PSYCHOTROPIC SUBSTANCES
1. Psychotropic Substances of I-P Group
| Seq. |
International recommended names |
Other names |
Chemical determinations |
|
|
1 |
2 |
3 |
| 1. |
|
2A-I, 2-indanoamine |
2,3-dihydro-1 H -inden-2-amine |
| 2. |
|
2-AT, 2-aminotetraline |
2-amino-1,2,3,4-tetrahydronaphthalene |
| 3. |
|
2C-I |
2,5-Dimethoxy-4-iodophenethylamine |
| 4. |
|
2C-T-2 |
2,5-Dimethoxy-4-ethylthiophenethylamine |
| 5. |
|
2C-T-7 |
2,5-dimethoxy-4-n-propylthiophenethylamine |
| 6. |
|
3F-MA |
3-fluoromethamphetamine, or 1-(3-fluorophenyl)- N -methylpropan-2-amine |
| 7. |
|
25B-NBOMe |
2-(4-bromo-2,5-dimethoxyphenyl)- N -(2-methoxybenzyl) ethylamine |
| 8. |
|
25C-NBOMe 2C-C-NBOMe |
2-(4-chloro-2,5-dimethoxyphenyl)- N -(2-methoxybenzyl) ethylamine |
| 9. |
|
25D-NBOMe |
2-(2,5-dimethoxy-4-methylphenyl) -N-(2-methoxybenzyl) ethylamine |
| 10. |
|
25E-NBOMe |
2-(2,5-dimethoxy-4-ethylphenyl)- N -(2-methoxybenzyl) ethylamine |
| 11. |
|
25G-NBOMe |
2-(2,5-dimethoxy-3,4-dimethylphenyl) -N-(2-methoxybenzyl) ethylamine |
| 12. |
|
25H-NBOMe |
2-(2,5-dimethoxyphenyl)- N -(2-methoxybenzyl) ethylamine |
| 13. |
|
25I-NBOMe |
2-(2,5-dimethoxy-4-iodofenyl)- N -(2-methoxybenzyl) ethylamine |
| 14. |
|
25I-NBMD NBMD-2C-I |
2-(2,5-dimethoxy-4-iodofenyl)- N -(2,3-methylenedioxybenzyl) ethylamine |
| 15. |
|
25N-NBOMe |
2-(2,5-dimethoxy-4-nitrophenyl)- N -(2-methoxybenzyl) ethylamine |
| 16. |
BREFEDRON |
4-bromometkatynone, 4-BMC, 4-BMAP |
1-(4-bromophenyl) -2-methylaminopropan-1-one |
| 17. |
BROLAMFETAMINE |
DOB |
4-Bromo-2,5-dimethoxyamphetamine, or 1-(4-bromo-2,5-dimethoxyphenyl) propan-2-amine |
| 18. |
BUFEDRONE |
α-(methylamino) butyrofenone |
1-Phenyl-2-(methylamino) butan-1-one |
| 19. |
BUTYLON |
|
1-(1,3-benzodioxy-5-yl) -2-(methylamino) butan-1-one |
| 20. |
|
DET |
N , N -diethyltryptamine |
| 21. |
|
DMA |
(+/-)-2,5-dimethoxy-α-methylphenethylamine, or 2,5-dimethoxyamphetamine |
| 22. |
|
DOET |
(+/-)-2,5-dimethoxy-4-ethyl-α-methylphenethylamine, or 2,5-dimethoxy-4-ethylamphetamines |
| 23. |
|
DMHP |
3-(1,2-dimethylheptyl) -1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6 H -dibenzo [ b , d ] pyran |
| 24. |
|
DMT |
N , N -dimethyltryptamine |
| 25. |
3.4-DMMC |
3,4-dimethylmethandimethylone |
1-(3,4-dimethylphenyl) -2-(methylamino) propan-1-one |
| 26. |
D2PM |
Difenyloprolinol |
Diphenyl (pyrrolidin-2-yl) methanol |
| 27. |
|
2-DPMP Deoxypipradrol |
2-diphenylmethylpiperidine |
| 28. |
DIBUTYLONE |
|
2-dimethylamino-1-(3,4-methylenedioxyphenyl) butan-1-one |
| 29. |
|
Euthylone |
1-(1,3-benzodioxol-5-yl) -2-(ethylamino) butan-1-one |
| 30. |
ETRYPTAMINE |
|
3-(2-aminobutyl) indole |
| 31. |
|
N-Ethyl-MDA, MDEA |
(+ /-)- N -ethyl-α-methyl-3,4-(methylenedioxy)-phenethylamine |
| 32. |
|
N-Hydroxy-MDA |
(+ /-)- N -[ α-methyl-3,4-(methylenedioxy) phenethyl] hydroxylamine |
| 33. |
|
Metkatynone |
2-(methylamino) -1-phenylpropan-1-one |
| 34. |
|
4-Methylaminorex |
(+ /-)- cis -2-amino-4-methyl-5-phenyl-2-oxazoline |
| 35. |
|
4-MTA |
α-methyl-4-methylthiophenethylamine, or 4-methylthioamphetamine |
| 36. |
ETHYLENE |
|
2-ethylamino-1-(3,4-methylenedioxyphenyl) propan-1-one |
| 37. |
|
4-AcO-DiPT |
4-acetoxy- N , N -diisopropyltryptamine |
| 38. |
|
4-AcO-DMT |
4-acetoxy- N , N -dimethyltryptamine |
| 39. |
|
4-AcO-MET |
4-acetoxy- N -ethyl- N -methyltryptamine |
| 40. |
4-EMC |
4-ethylmethkatinone 2-ethylamino-1-p-tolylpropane-1-one |
2-methylamino-1-(4-ethylphenyl) propan-1-one 1-(4-ethylphenyl) -2-methylaminopropan-1-one |
| 41. |
3-FMC |
3-fluorometkatinone |
1-(3-fluorophenyl) -2-(methylamino) propan-1-one |
| 42. |
4-FMC |
4-fluorometkatinone |
2-methylamino-1-(4-fluorophenyl) propan-1-one, or 1-(4-fluorophenyl) -2-methylaminopropan-1-one |
| 43. |
|
4-HO-DiPT |
4-hydroxy- N , N -diisopropyltryptamine |
| 44. |
|
4-HO-MET |
4-hydroxy- N -ethyl- N -methyltryptamine |
| 45. |
|
5-IT |
5-(2-aminopropyl) indole |
| 46. |
4-MEC |
4-methyl- N -ethyloatinone |
2-ethylamino-1-(4-methyl-phenyl) propane-1-one |
| 47. |
|
5-MAPB |
1-(benzofuran-5-yl)- N -methyl propan-2-amine |
| 48. |
3-MMC |
|
1-(3-methylphenyl) -2-(methylamino) propan-1-one |
| 49. |
|
5-MeO-DALT |
5-methoxy- N , N -diallilo-tryptamine |
| 50. |
|
5-MeO-DMT |
5-methoxy- N , N -dimethyltryptamine |
| 51. |
|
5-MeO-MiPT |
5-methoxy- N -methyl- N -isopropyltryptamine |
| 52. |
|
5-APB |
1-(benzofuran-5-yl) propane-2-amine |
| 53. |
|
6-APB |
1-(benzofuran-6-yl) propane-2-amine |
| 54. |
|
6-APDB |
1-(2,3-dihydro-1-benzofuran-6-yl) propane-2-amine |
| 55. |
ETKATYNON |
N-ethyloatinone |
2-(ethylamino) -1-phenylpropan-1-one |
| 56. |
ETHICCYCLIDINE |
PCE |
N -ethyl-1-phenylocyclohexylamine |
| 57. |
FLUOROAMPHETAMINA |
4-fluoroamphetamine 4-FMP 4-FA |
1-(4-fluorophenyl) -2-aminopropane |
| 58. |
HEXSEDRON |
|
1-Phenyl-2-(methylamino) hexan-1-one |
| 59. |
|
Iso-pentedrone |
1-methylamino-1-phenyl-pentan-2-one |
| 60. |
KATYNON |
|
(-)-α-aminopropionofenone |
| 61. |
(+) -LIZERGID |
LSD, LSD-25 |
9,10-didehydro-6-methylergolino-8β-carboxylic acid diethylamide |
| 62. |
|
MDMA |
(+ /-) -3,4-methylenedioxy- N , α-dimethylphenethylamine, or 3,4-methylenedioxymetamfetamine |
| 63. |
|
MDPBP |
1-(3,4-methylenedioxyphenyl) -2-(pyrrolidin-1-yl) butan-1-one |
| 64. |
|
MDPPs |
1-(3,4-methylenedioxyphenyl) -2-(1-pyrrolidinyl) -1-propanone |
| 65. |
|
MMDA |
(+/-)-5-methoxy-3,4-methylenedioxy-α-methylphenethylamine, or 5-methoxy-3,4-methylenedioxy-amphetamines |
| 66. |
|
Mescaline |
3,4,5-trimethoxyphenethylamine |
| 67. |
|
MPBP |
1-(4-methylphenyl) -2-(pyrrolidin-1-yl) butan-1-one |
| 68. |
|
pMPPP |
1-(4-methylphenyl) -2-(pyrrolidin-1-yl)-propan-1-one |
| 69. |
|
Parahexyl |
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo [ b , d ] pyran |
| 70. |
|
PBP Alpha-PBP α-PBP |
1-Phenyl-2-(pyrrolidin-1-yl) butan-1-one |
| 71. |
|
PMA |
4-methoxy-α-methylphenethylamine, or para-methoxyamphetamina |
| 72. |
|
PMMA |
4-methoxy- N , α-dimethylphenethylamine, or p-methoxymetamfetamine |
| 73. |
|
Psylocin 4-HO-DMT |
3-(2-dimethylaminoethyl) -4-hydroxyindole |
| 74. |
MEFEDRON |
4-methylmethkatinone |
(+ /-) -2-methylamino-1-(4-methylphenyl) propan-1-one |
| 75. |
METAMFEPRAMON |
Dimethyloatinone Dimethylpropion Dimethylpipion |
(RS) -2-dimethylamino-1-phenylpropan-1-one |
| 76. |
METEDRON |
4-methoxymetkatynone bk-PMMA PMMC |
1-(4-methoxyphenyl) -2-(methylamino) propan-1-one |
| 77. |
METHYLENE |
Bk-MDMA 3,4-methylenedioximetkatynone |
1-(1,3-benzodioxol-5-yl) -2-(methylamino) propan-1-one |
| 78. |
|
Methylobufedrone |
2-(methylamino) -1-(4-methylphenyl) butan-1-one |
| 79. |
|
Ethylobufedrone N-ethylobufedrone NEB |
1-Phenyl-2-(ethylamino) butan-1-one |
| 80. |
NAFYRON |
0-2482 |
1-naphthalen-2-yl-2-pyrrolidin-1-ylopentan-1-one |
| 81. |
PENTEDRON |
α-methylaminovalerophenone |
1-Phenyl-2-(methylamino) pentan-1-one |
| 82. |
PENTYLONE |
bk-Metyl-K, bk-MBDP |
1-(3,4-methylenedioxyphenyl) -2-(methylamino) pentan-1-one |
| 83. |
PSILOCYBIN |
|
3-(2-dimethylaminoethyl) -4-indolil dihydrogen phosphate |
| 84. |
|
Proscaline |
2-(3,5-dimethoxy-4-propoxyphenyl) ethylamine |
| 85. |
|
RH-34 |
3-[ 2-[ (2-methoxyphenyl) methylamino] ethyl] -1 H -quinazolino-2,4-dione |
| 86. |
ROLICYCLIDINE |
PHP, PCPY |
1-(1-phenyloccyclohexyl) pyrrolidine |
| 87. |
|
STP, DOM |
2-amino-1-(2,5-dimethoxy-4-methylphenyl) propane |
| 88. |
TENAMFETAMINE |
MDA |
3,4-methylenedioxyamphetamine |
| 89. |
TENOCYCLIDINE |
TCP |
1-[ 1-(2-thienyl) cyclohexyl] piperidine |
| 90. |
|
TMA |
(+/-)-3,4,5-trimethoxy-α-methylphenethylamine, or 3,4,5-trimethamphetamina |
| 91. |
|
TMA-2 |
2,4,5-trimethoxyamphetamine |
| 92. |
|
TMA-6 2,4,6-trimethoxyamphetamina |
1-(2,4,6-trimethoxyphenyl) propan-2-amine |
| 93. |
|
Tetrahydrocannabinols |
The following isomers and their stereochemical variants: -7,8,9,10-tetrahydro-6,6,9-trimethyl-3-pentyl-6 H -dibenzo [ b , d ] pyran-1-ol, -(9 R , 10a R ) -8,9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl- 6H -dibenzo [ b , d ] pyran-1-ol, -(6a) R , 9 R , 10a R ) -6a, 9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6 H -dibenzo [ b , d ] pyran-1-ol, -(6a) R , 10a R ) -6a, 7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6 H -dibenzo [ b , d ] pyran-1-ol, -6a, 7,8,9-tetrahydro-6,6,9-trimethyl-3-pentyl-6 H -dibenzo [ b, d ] pyran-1-ol, -(6a) R , 10a R ) -6a, 7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-6 H -dibenzo [ b , d ] pyran-1-ol |
| and: -the salts of the substances in this group whenever the existence of such salts is possible, -the stereoisomers of substances in this group, if such stereoisomers are possible within the chemical designation used, unless such stereoisomers are clearly excluded. |
|||
2. Psychotropic Substances of II-P Group
| Seq. |
International recommended names |
Other names |
Chemical determinations |
|
|
1 |
2 |
3 |
| 1. |
|
4-BEC 4-bromoetkatinone |
1-(4-bromophenyl) -2-ethylaminopropan-1-one |
| 2. |
|
2C-B |
4-bromo-2,5-dimethoxyphenethylamine |
| 3. |
|
2C-C |
2-(4-chlorophenyl-2,5-dimethoxy) ethylamine |
| 4. |
|
2C-D |
2-(2,5-dimethoxy-4-methylphenyl) ethylamine |
| 5. |
|
2C-G |
2-(2,5-dimethoxy-3,4-dimethylphenyl) ethylamine |
| 6. |
|
2C-N |
2-(2,5-dimethoxy-4-nitrophenyl) ethylamine |
| 7. |
|
2C-P |
2-(2,5-dimethoxy-4-propylphenyl) ethylamine |
| 8. |
|
3-MeO-PCE 3-Methoxyethyciclidine |
N -ethyl-1-(3-methoxyphenyl) cyclohexylamine |
| 9. |
|
3-MeO-PCP 3-Methoxyphencyclidine |
1-[ 1-(methoxyphenyl) cyclohexyl] piperidine |
| 10. |
AMFETAMINE |
Psychedrine |
(+ /-) -2-amino-1-phenylpropanoate |
| 11. |
AMINEPTINE |
|
7-[ (10,11-dihydro-5 H -dibenzo [ a, d] cyclohepten-5-yl) amino]-heptanic |
| 12. |
BENZYLPIPERAZINE |
BZP |
1-benzylopiperazine, or 1-benzyl-1,4-diazacyclohexane |
| 13. |
DBZP |
Dibenzylpiperazine |
1,4-dibenzylpiperazine |
| 14. |
DEKSAMFETAMINE |
|
(+) -2-amino-1-phenylpropanoate |
| 15. |
ETHYLPHENIDATE |
|
Ethyl 2-phenyl-2-(piperidin-2-yl) acetate |
| 16. |
FENCYCLIDINE |
PCP |
1-(1-phenyloccyclohexyl) piperidine |
| 17. |
FENETHYLLINE |
|
(+ /-) -3,7-dihydro-1,3 -dimethyl-7-[ 2-[ (1-methyl-2-phenethyl)-amino]-ethyl] -1H - puryne-2,6-dione |
| 18. |
FENMETRAZINE |
|
2-Phenyl-3-methylmorpholine |
| 19. |
KETAMINE |
|
2-(2-chlorophenyl) -2-(methylamino)-cyclohexane |
| 20. |
gamma-hydroxymasbutyric acid |
GHB |
4-hydroxybutanoic acid |
| 21. |
LEWAMFETAMINE |
|
(-)-α-methylphenethylamine |
| 22. |
LEWOMETAMFETAMINE |
|
(-) -1- N , α-dimethylphenethylamine |
| 23. |
4-methylamphetamine |
4-MA |
1-(4-methylphenyl) propane-2-amine, or 1-(4-methylphenyl) -2-aminopropane (4-MA) |
| 24. |
MBZP |
|
1-benzyl-4-methylpiperazine |
| 25. |
|
mCPP |
1-(3-chlorophenyl) piperazine |
| 26. |
MEKLOKWALON |
|
3-(o-chlorophenyl) -2-methyl-4 (3 H )-quinazolinone |
| 27. |
MeOPP |
pMPP, 4-MPP, Paraperazine |
1-(4-methoxyphenyl) piperazine |
| 28. |
METAKWALON |
|
2-methyl-3-(o-tolyl) -4 (3 H )-quinazolinone |
| 29. |
METAMFETAMINE |
Metamfetamine racemic |
(+) -2-methylamino-1-phenylpropane (+ /-) -2-methylamino-1-phenylpropane |
| 30. |
METIOPROPAMINE |
MPA |
N -methyl-1-(thiophen-2-yl) propan-2-amine |
| 31. |
METOKSETAMINE |
MXE |
2-(3-methoxyphenyl) -2-(ethylamino) cyclohexanone |
| 32. |
METHYLPHENIDATE |
Ritalin |
Α-phenyl-(2-piperidyno)-acetic acid methyl ester |
| 33. |
PENTAZOCINE |
Fortral |
(2 R *, 6 R *, 11 R *) -1,2,3,4,5,6-hexahydro-8-hydroxy-6,11-dimethyl-3-(3-methyl-2-butenyl) -2,6-methane-3-benzazocine |
| 34. |
pFPP |
4-fluorophenylpiperazine |
1-(4-fluorophenyl) piperazine |
| 35. |
SALWINORINE A |
|
9-acetoxy-2-(furan-3-yl) -6a, 10b-dimethyl-4,10-dioxododekahydro-1 H -benzo [ f ] methyl isochromene-7-carboxylate |
| 36. |
SEKOBARBITAL |
|
5-allyl-5-(1-methylbutyl) barbituric acid |
| 37. |
|
The 9 -tetrahydrocannabinol and its stereochemical variants |
(6a) R , 10a R ) -6a, 7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6 H -dibenzo [ b , d ] pyran-1-ol |
| 38. |
TFMPP |
3-trifluoromethylphenylpiperazine |
1-[ 3-(trifluoromethyl) phenyl] piperazine |
| 39. |
ZIPEPROL |
|
α-(α-methoxybenzyl-4-β-methoxyphenyl)-1-piperazinethanol |
| and: -the isomers of psychotropic substances listed in this group, if such isomers are possible under the chemical designation used, unless such isomers are clearly excluded, -the esters and ethers of psychotropic substances listed in this group, if such esters and ethers are possible, unless they are listed in another group, -the salts of psychotropic substances listed in this group, including the salts of esters, ethers and isomers referred to above, if such salts are possible. |
|||
3. Psychotropic Substances Group III-P
| International |
Other names |
Chemical determinations |
| 1 |
2 |
3 |
| AMOBARBITAL |
Amytal |
5-ethyl-5-isopentylobarbitoric acid |
| BUPRENORFINA |
|
21-cyclopropyl-7- α -[ ( S ) -1-hydroxy-1,2,2-trimethylpropyl] -6,14- endo -ethane-6,7,8,14-tetrahydrooripawine |
| BUTALBITAL |
|
5-allyl-5-isobutylobarbitoric acid |
| CYCLOBARBITAL |
|
5-(1-cyclohexen-1-yl) -5-ethylobarbitoric acid |
| FLUNITRAZEPAM |
|
5-( at -fluorophenyl) -1,3-dihydro-1-methyl-7-nitro-2 H -1,4-benzodiazepin-2-one |
| GLUTETIMID |
Glimid |
3-Ethyl-3-phenyl-2,6-dioxopiperidine |
| KATYNA |
|
(+)- treo -2-amino-1-hydroxy-1-phenylpropane |
| PENTOBARBITAL |
Nembutal |
5-ethyl-5-(1-methylbutyl)-barbituric acid |
| and salts of the substances in this group whenever the existence of such salts is possible |
||
4. psychotropic Substances of IV-P Group
| Seq. |
International recommended names |
Other names |
Chemical determinations |
|
|
1 |
2 |
3 |
| 1. |
|
Alpha-PHP α-PHP |
1-Phenyl-2-(pyrrolidin-1-yl) hexan-1-one |
| 2. |
|
Alpha-PPP α-PPP |
1-Phenyl-2-(pyrrolidin-1-yl) propan-1-one |
| 3. |
|
Alpha-PVP α-PVP |
1-Phenyl-2-(pyrrolidin-1-yl) pentan-1-one |
| 4. |
ALLOBARBITAL |
|
5,5-diallilobarbitric acid |
| 5. |
ALPRAZOLAM |
|
8-chloro-6-phenyl-1-methyl-4 H -s-triazolo [ 4,3-a] [ 1, 4] benzodiazepine |
| 6. |
AMFEPRAMON |
Diethylpropion |
2-diethylamino-1-phenyle-1-propanone |
| 7. |
AMINOREX |
|
2-Amino-5-Phenyl-2-oxazoline |
| 8. |
BARBITAL |
Veronalum |
5,5-diethylobarbitoric acid |
| 9. |
BENZFETAMINE |
|
N -benzyl- N -α-dimethyl-phenethylamine |
| 10. |
BROMAZEPAM |
|
7-bromo-1,3-dihydro-5-(2-pyridyl) -2 H -1,4-benzodiazepin-2-one |
| 11. |
BROTIZOLAM |
|
2-bromo-4-(o-chlorophenyl) -9-methyl-6 H -thieno [ 3,2-f]-s-triazolo [ 4,3-a] [ 1, 4] diazepine |
| 12. |
BUTOBARBITAL |
|
5-butyl-5-ethylobarbitoric acid |
| 13. |
2C-E |
2,5-dimethoxy-ethylphenylethylamine |
1-(2,5-dimethoxy-4-ethylphenyl) -2-aminoethane |
| 14. |
|
4-Cl-α-PPP 4-chloro-alpha-PPP |
1-(4-chlorophenyl) -2-(pyrrolidin-1-yl) propan-1-one |
| 15. |
CHLORDIAZEPOKSYD |
Elenium |
4-oxoc-7-chloro-5-phenyl-2-(methylamino) -3 H -1,4-benzodiazepines |
| 16. |
DELORAZEPAM |
|
7-chloro-5-(o-chlorophenyl) -1,3-dihydro-2 H -1,4-benzodiazepin-2-one |
| 17. |
DIAZEPAM |
Relanium |
7-chloro-5-phenyl-1,3-dihydro-1-methyl-2 H -1,4-benzodiazepin-2-one |
| 18. |
ESTAZOLAM |
|
8-chloro-6-phenyl-4 H -s-triazolo [ 4,3-a] [ 1, 4] benzodiazepine |
| 19. |
ETCHLORINE |
|
1-chloro-3-ethyl-1-pentene-4-in-3-ol |
| 20. |
ETYLAMFETAMINE |
|
(+ /-)- N -ethyl-α-methylphenethylamine, or N -Ethylamphetamine |
| 21. |
ETYNAMAT |
|
1-Ethylcyclohexyl ester of carbalamine acid |
| 22. |
FENDIMETRAZINE |
|
(+) -3,4-dimethyl-2-phenylomorfoline |
| 23. |
FENCAMFAMINE |
|
(+ /-) -N- ethyl - 3-Phenylobicyclo [ 2.2.1] heptane-2-amine |
| 24. |
PHENOBARBITAL |
Luminalum |
5-ethyl-5-phenylobarbitric acid |
| 25. |
FENPROPOREKS |
|
(+ /-) -3-[ (α-methylphenethyl) amino] propionitrile |
| 26. |
FENTERMINE |
|
α, α-dimethylphenethylamine |
| 27. |
FLUDIAZEPAM |
|
7-chloro-5-(o-fluorophenyl) -1,3-dihydro-1-methyl-2 H -1,4-benzodiazepin-2-one |
| 28. |
FLURAZEPAM |
|
7-chloro-1-[ 2-(diethylamino) ethyl] -5-(o-fluorophenyl) -1,3-dihydro-2 H -1,4-benzodiazepin-2-one |
| 29. |
HALAZEPAM |
|
7-chloro-5-phenyl-1,3-dihydro-1-(2,2,2-trifluoroethyl) -2- H -1,4-benzodiazepin-2-one |
| 30. |
HALOXAZOLAM |
|
10-bromo-11 b -(o-fluorophenyl) -2,3,7,11 b - tetrahydrooxazolo [ 3,2- d ] [ 1, 4]-benzodiazepin-6 (5 H )-one |
| 31. |
KAMAZEPAM |
|
7-chloro-5-phenyl-1,3-dihydro-3-hydroxy-1-methyl-2 dimethylcarbamate H -1,4-benzodiazepin-2-one |
| 32. |
KETAZOLAM |
|
11-chloro-12b-phenyl-8,12 b -dihydro-2,8-dimethyl-4 H -[ 1, 3]-oxazinate-[ 3,2- d ] [ 1, 4] benzodiazepine-4,7 (6 H )-dione |
| 33. |
KLOBAZAM |
|
7-chloro-5-Phenyl-1-methyl-1 H -1,5-benzodiazepino-2,4 (3 H , 5 H )-dione |
| 34. |
KLOXAZOLAM |
|
10-chloro-11 b -( at -chlorophenyl) -2,3,7,11 b -tetrahydrooxazolo-[ 3,2- d ] [ 1, 4] benzodiazepin-6 (5 H )-one |
| 35. |
KLONAZEPAM |
Rivotril |
5-(o-chlorophenyl) -1,3-dihydro-7-nitro-2 H -1,4-benzodiazepin-2-one |
| 36. |
CLORAZEPATE |
|
7-chloro-5-phenyl-2,3-dihydro-2-oxso-1 H -1,4-benzodiazepine-3-carboxylic acid |
| 37. |
KLOTIAZEPAM |
|
5-( at -chlorophenyl) -7-ethyl-1,3-dihydro-1-methyl-2 H -thieno [ 2,3-e] -1,4-diazepin-2-one |
| 38. |
LEFETAMINE |
SPA |
(-) -1-dimethylamino-1,2-diphenylethane, or (-)- N , N -dimethyl-1,2-diphenylethylamine |
| 39. |
ETHYL LEFLAZEPIANOATE |
|
ethyl ester of 7-chloro-5 acid-( at -fluorophenyl) -2,3-dihydro-2-oxo-1 H -1,4-benzodiazepine-3-carboxylic acid |
| 40. |
LOPRAZOLAM |
|
6-( at -chlorophenyl) -2,4-dihydro-2-[ (4-methyl-1-piperazinyl) methylene] -8-nitro-1 H -imidazo [ 1,2-a] [ 1, 4] benzodiazepin-1-one |
| 41. |
LORAZEPAM |
|
7-chloro-5-( at -chlorophenyl) -1,3-dihydro-3-hydroxy-2 H -1,4-benzodiazepin-2-one |
| 42. |
LORMETAZEPAM |
|
7-chloro-5-( at -chlorophenyl) -1,3-dihydro-3-hydroxy-1-methyl-2 H -1,4-benzodiazepin-2-one |
| 43. |
MAZINDOLE |
|
5-( p -chlorophenyl) -2,5-dihydro-3 R -imidazo [ 2,1-a]-isoindol-5-ol |
| 44. |
MDPEA |
3,4-methylenedioxyphenylethylamine Methylenedioxyphenylethylamine, homopiperonylamine |
3,4-methylenedioxy-2-phenylethylamine |
| 45. |
MDPV |
MDαPVP MDPK |
1-(1,3-benzodioxy-5-yl) -2-pyrrolidine-1-ylpentan-1-one |
| 46. |
MEDAZEPAM |
Rudotel |
7-chloro-5-phenyl-2,3-dihydro-1-methyl-1 H -1,4-benzodiazepine |
| 47. |
MEFENOREX |
|
(+ /-)- N -(3-chloropropyl)-α-methylphenethylamine |
| 48. |
MEPROBAMATE |
|
2,2-di (carbamoyloxymethyl) pentane, or 2-methyl-2-propyl-1,3-propanediol dicarbamate |
| 49. |
METHYLPHENOBARBITAL |
Prominalum |
5-ethyl-5-phenyl-N-methylobarbitoric acid |
| 50. |
METYPRILON |
|
3,3-diethyl-5-methyl-2,4-piperidinedione |
| 51. |
MEZOCARB |
|
3-(α-methylphenyl)- N -(Phenylcarbamoyl)-sidnonimine |
| 52. |
MIDAZOLAM |
|
8-chloro-6-( at -fluorophenyl) -1-methyl-4 H -imidazo [ 1,5-a] [ 1, 4] benzodiazepine |
| 53. |
MMDPEA |
5-Methoxy-MDPEA |
2-(7-methoxy-1,3-benzodioxol-5-yl) ethylamine |
| 54. |
NIMETAZEPAM |
|
5-Phenyl-1,3-dihydro-1-methyl-7-nitro-2 H -1,4-benzodiazepin-2-one |
| 55. |
NITRAZEPAM |
|
5-Phenyl-1,3-dihydro-7-nitro-2 H -1,4-benzodiazepin-2-one |
| 56. |
NORDAZEPAM |
|
7-chloro-5-Phenyl-1,3-dihydro-2 H -1,4-benzodiazepin-2-one |
| 57. |
OKSAZEPAM |
|
7-chloro-5-phenyl-1,3-dihydro-3-hydroxy-2 H -1,4-benzodiazepin-2-one |
| 58. |
OXAZOLAM |
|
10-chloro-11 b -Phenyl-2,3,7,11 b -tetrahydro-2-methyloxazolo [ 3,2- d ] [ 1, 4] benzodiazepin-6 (5 H )-one |
| 59. |
PEMOLINA |
|
2-Amino-5-phenyl-2-oxazolin-4-one, or 5-phenyl-2-imino-4-oxazolidinone |
| 60. |
PINAZEPAM |
|
7-chloro-5-phenyl-1,3-dihydro-1-(2-propionyl) -2 H -1,4-benzodiazepin-2-one |
| 61. |
PIPRADROL |
|
1,1-diphenyl-1-(2-piperidyl) methanol |
| 62. |
PIROWALERONE |
|
(+ /-) -1-(4-methylphenyl) -2-(1-pyrrolidinyl) -1-pentanon |
| 63. |
PRAZEPAM |
|
7-chloro-1-(cyclopropylomethyl) -5-phenyl-1,3-dihydro-2 H -1,4-benzodiazepin-2-one |
| 64. |
SECBUTABARBITAL |
|
5-sec-butyl-5-ethylobarbitoric acid |
| 65. |
TAPENTADOL |
|
3-[ 3-(dimethylamino) -1-ethyl-2-methylpropyl] phenol |
| 66. |
TEMAZEPAM |
Signopam |
7-chloro-5-phenyl-1,3-dihydro-3-hydroxy-1-methyl-2 H -1,4-benzodiazepin-2-one |
| 67. |
TETRAZEPAM |
|
7-chloro-5-(cyclohexen-1-yl) -1,3-dihydro-1-methyl-2 H -1,4-benzodiazepin-2-one |
| 68. |
TRIAZOLAM |
|
8-chloro-6-(o-chlorophenyl) -1-methyl-4 H - seconds -triazolo [ 4,3- α ] [ 1, 4] benzodiazepine |
| 69. |
WINYLBITAL |
|
5-(1-methylbutyl) -5-vinylobarbitoric acid |
| 70. |
ZALEPLON |
|
N -(3-(3-cyanopyrazolo [ 1,5-a] pyrimidin-7-yl) phenyl)- N -ethylacetamide |
| 71. |
ZOLPIDEM |
|
N , N , 6-trimethyl-2-(4-methylphenyl) imidazo [ 1,2- α ] pyridine-3-acetamide |
| 72. |
Zopiclone |
|
6-(5-chloropyridin-2-yl) -7-oxo-6,7-dihydro-5-carboxylate 4-methylpiperazine-1-carboxylate H -pirolo [ 3,4- b ] Iraq-5-yl |
| and salts of the substances in this group whenever such salts are possible. |
|||
[ 1] Article 2 (1) 2 in the version set by the Article. 23 point 1 of the Act of 11 September 2015. o public health (Journal of Laws of the European Union 1916). The amendment came into force on 1 January 2016.
[ 2] Article 6 (1) 3 point 1 repealed by Article 23 point 2 (a) a) of the Act of 11 September 2015. o public health (Journal of Laws of the European Union 1916). The amendment came into force on 1 January 2016.
[ 3] Article 6 (1) 3 point 2 repealed by Article 23 point 2 (a) a) of the Act of 11 September 2015. o public health (Journal of Laws of the European Union 1916). The amendment came into force on 1 January 2016.
[ 4] Article 6 (1) 3 point 12 (a) (k) repealed by Article 23 point 2 (a) b) of the Act of 11 September 2015. o public health (Journal of Laws of the European Union 1916). The amendment came into force on 1 January 2016.
[ 5] Article 7, as amended by Article 2, 23 point 3 of the Act of 11 September 2015. o public health (Journal of Laws of the European Union 1916). The amendment came into force on 1 January 2016.
[ 6] Article 8, repealed by Article 8. 23 point 4 of the Act of 11 September 2015. o public health (Journal of Laws of the European Union 1916). The amendment came into force on 1 January 2016.
[ 7] Article 9 (1) 1 in the wording set by Article 1. 23 point 5 of the Act of 11 September 2015. o public health (Journal of Laws of the European Union 1916). The amendment came into force on 1 January 2016.
[ 8] Article 10 (1) 2 in the version set by the Article. 23 point 6 of the Act of 11 September 2015. o public health (Journal of Laws of the European Union 1916). The amendment came into force on 1 January 2016.
[ 9] Article 15, point 4, as set out by the Article. 23 point 7 of the Act of 11 September 2015. o public health (Journal of Laws of the European Union 1916). The amendment came into force on 1 January 2016.
[ 10] Article 19 (1) 3 in the version set by the Article. 23 point 8 of the Act of 11 September 2015. o public health (Journal of Laws of the European Union 1916). The amendment came into force on 1 January 2016.
[ 11] On the basis of the judgment of the Constitutional Court of 14 February 2012. (Journal of Laws pos. 214) art. 56 par. 3 as regards the use of the meaning of "significant quantities" of the substances listed therein, is in accordance with the art. 42 par. 1 in connection with art. 2 of the Constitution.
[ 12] On the basis of the judgment of the Constitutional Court of 4 November 2014. (Journal of Laws pos. 1568) art. 62 ust. 1 to the extent that it concerns hemp other than non-wovens, it is in accordance with art. 47 in connection with art. 31 par. 3 Constitution of Poland.
[ 13] On the basis of the judgment of the Constitutional Court of 14 February 2012. (Journal of Laws pos. 214) art. 62 ust. 2 with regard to the use of the "significant quantity" of the substances referred to therein, is in accordance with the Article. 42 par. 1 in connection with art. 2 of the Constitution.
[ 14] On the basis of the judgment of the Constitutional Court of 4 November 2014. (Journal of Laws pos. 1568) art. 63 par. 1 to the extent that it concerns hemp other than non-wovens, it is in accordance with art. 47 in connection with art. 31 par. 3 Constitution of Poland.
[ 15] On the basis of the judgment of the Constitutional Court of 28 October 2015. (Journal of Laws pos. 2014) art. 70 par. 1 in so far as it allows a decision to be forfeited of an object for the commission of any of the offences listed in that provision, which is not the property of the perpetrator, if the holder or any other person entitled, despite the exercise of caution, that the circumstances required under the circumstances, were not foreseeable and could not have foreseen that it could be used to commit any of these offences, is incompatible with the art. 42 par. 1 in connection with art. 2 and Article 64 par. 1 and 3 in connection with art. 31 par. 3 Constitution of Poland. Article 70 (1) 1 in the above The extent of which is lost on 2 December 2015.
